



Griffin House, 53 Regent Place, Birmingham, B1 3NJ

Tel: +44 (0)121 236 1988

Website: www.bsac.org.uk

Charity No: 1093118 VAT No: 442 5855 40

Registered as a company limited by guarantee

in England & Wales No. 4443910

*Registered address: Griffin House, 53 Regent Place,
Birmingham, B1 3NJ*

ANNUAL GENERAL MEETING 2021

The next **Annual General Meeting** of the
British Society for Antimicrobial Chemotherapy
will be held at 14:30hrs on **Thursday 29th April 2021**

CONTENTS

	<i>page</i>
Agenda	2-9
Unconfirmed minutes of the Annual General Meeting 2020	10-12
Statement of Trustee's responsibility	13
Trustees Report	14-21
Independent Auditor's report	22-23
Financial Statements	24-37
Memorandum of Association	38-39
Articles of Association	40-46

Open to all Members of the BSAC

Voting rights limited to Ordinary and Honorary Members of the Society

AGENDA

- 1 Apologies for absence
- 2 To receive the minutes of the 2020 Annual General Meeting
- 3 President's report
- 4 Elections

To note in accordance with Article 7, the names of those elected to Ordinary Membership of the Society

BSAC Membership Elections September 2019 – October 2020

510 new members

A.Professor Sambo Obadiah Elkanah, International Health MSc Student, University Of Leeds, United Kingdom; Adeboye Olakunle Bamgboye, Pharmacist Demonstrator, Obafemi Awolowo University, Nigeria; Ass Prof Meher Rizvi, Associate Professor, Sultan Qaboos University, Oman; De Celia Souque, Postdoctoral Researcher, University of Oxford, United Kingdom; Diana K Gahn-Smith, National AMR Focal Point, Health Sector of Liberia, Liberia; Dr A K Peer, Consultant Microbiologist (Honorary), Lancet Laboratories, South Africa; Dr Abdul Rahman Al Mahrouqi, Medical Microbiologist, Oman Ministry of Health, Oman; Dr Abdul Wal United States of Americansa, Lecturer / Researcher, Islamic University in Uganda , Uganda; Dr Abosufyan Jamattallah Salama, Assistant Professor, University of Kordofan, Sudan; Dr Aisha Alamri, Assistant Professor , Imam Abdulrahman Bin Faisal University, Saudi Arabia; Dr Alabed Ali Alabed, Head of Community Medicine Department, Lincoln University College, United Kingdom; Dr Alice Maxwell, ST3 Combined Infection Training, Public Health Wales, United Kingdom; Dr Aliyu Ibrahim, Lecturer, Usmanu Danfodiyo University , Nigeria; Dr Allan Abbott, Medical Science Liaison, A. Menarini Farmaceutica Internazionale, United Kingdom; Dr Alma Serrano, Microbiologist, Laboratorio Saenz Renauld, Costa Rica; Dr Amandeep Dhugga, Trust Grade Doctor in Microbiology and Infectious diseases, Nottingham University Hospitals Trust, United Kingdom; Dr Amy Edwards, Junior Doctor, Barts Health NHS Trust, United Kingdom; Dr Ana Vale, Lecturer in Veterinary Public Health, University College Dublin, Ireland; Dr Anastasios Tsaousis, Senior Lecturer in Molecular & Evolutionary Parasitology, University of Kent, United Kingdom; Dr Andrew Wilkinson, Principal Medicinal Chemist, Team Leader, AMR Centre, United Kingdom; Dr Andrzej Szewczak-Harris, Research Associate, University of Cambridge, United Kingdom; Dr Angel Boulos, Consultant Microbiologist, Southern Health and Social Care Trust, United Kingdom; Dr Anna Goodman, Consultant Infectious Diseases, Guy's and St Thomas NHS Foundation Trust, United Kingdom; Dr Apostolos Liakopoulos, Postdoctoral Researcher, Leiden University, Netherlands; Dr Arash Arianpoor, Family Practice Physician, Sabzevar University of Medical Sciences, Iran; Dr Asmaa Badawy, Senior Clinical Pharmacist, The Memorial Souad Kafafi University Hospital, Egypt; Dr Athanasios Mamarelis, CT2 Endocrine & Diabetes, Nottingham University Hospitals NHS Trust, United Kingdom; Dr Ayesha Sadaf, Research Associate, Institute of Genomics and Integrative Biology, India; Dr Balaji Veeraraghavan, Professor, Christian Medical College, India; Dr Belinda Loh, Postdoctoral Scientist, Zhejiang University-University of Edinburgh Institute, China; Dr Benedict Rogers, SpR/ST6 ID/Microbiology, University Hospitals of Leicester NHS Trust, United Kingdom; Dr Berkin Hack, Microbiology and Infectious Diseases Registrar, NHS / London School of Tropical Medicine, United Kingdom; Dr Bethan Walsh, Consultant in Infectious Diseases and OPAT, Nottingham University Hospitals NHS Trust, United Kingdom; Dr Beverley Anne Furber, Nursery Worker, Easton Community Children's Centre, United Kingdom; Dr Bir United Kingdom; Tesfaye Birhanu, Postdoctoral Researcher, Kyungpook National University, South Korea; Dr Bradley Langford, Pharmacist, Public Health Ontario, United States of America; Dr Bunpote Siridechadilok, Research Team Head, National Centre for genetic Engineering and Biotechnology, Thailand; Dr C Kannangara, MTI Trainee Registrar Microbiology, Watford General Hospital West Hertfordshire NHST, United Kingdom; Dr Callum Mutch, Speciality Registrar, NHS Lothian, United Kingdom; Dr Caoimhe Brennan, Clinical Lecturer in Microbiology, Royal College of Surgeons Ireland, Ireland; Dr Caroline Williams, SpR ID/MM, University Hospitals of Leicester NHS Trust, United Kingdom; Dr Catherine H Tremlett, Consultant Microbiologist, Norfolk and Norwich University Hospitals NHSFT, United Kingdom; Dr Cathleen Chan, ST3, University Hospital Coventry, United Kingdom; Dr Catrin Moore, Research Group Leader, University of Oxford, United Kingdom; Dr Charles Akugbey Narh, Research Officer, Burnet Institute for Medical Research, Australia; Dr Charlotte Brookfield, ST5 Doctor in Medical Microbiology, Manchester Foundation Trust, United Kingdom; Dr Charlotte Milne, ST4 Combined Infection Training, LET Health Education North East, United Kingdom; Dr Chizaram Anselm Onyeaghala, Senior Resident, University of Port Harcourt Teaching hospital Nigeria, Nigeria; Dr Christianne Micallef, Principal Pharmacist-Antimicrobials, Cambridge University Hospitals NHS FT, United Kingdom; Dr Christopher Keil, CT2 Doctor, Sheffield Teaching Hospitals, United Kingdom; Dr Christopher Lawrence Grigsby, Postdoctoral Fellow, Karolinska Institute, Sweden; Dr Christopher Lynch, Microbiology SpR, Sheffield Teaching Hospital, United Kingdom; Dr Christopher Smith, ST3 Combined Infection Training, Royal Liverpool University Hospital, United Kingdom; Dr Ch United Kingdom; wuemekema Smart Obiagwu, Senior Registrar, University of Uyo Teaching Hospital, Nigeria; Dr Claire Pegg, Science Curriculum Director, University Technical College, United Kingdom; Dr Clarence Chiwenda, Laboratory Assistant, National Blood Service, Zimbabwe; Dr Colin Kelcey, Retired Neuroscientist, Retired, United Kingdom; Dr Dan Burns, Infectious Diseases Consultant, British Army, United Kingdom; Dr Daniel Pan, Academic

Clinical Fellow in Infectious Diseases, University of Leicester, United Kingdom
 Dr Daniela Heeg, Head of Research, CHAIN Biotechnology Ltd, United Kingdom
 Dr Daniele Meunier, Healthcare Scientist, Public Health England, United Kingdom
 Dr Daniella Spiteri Cornish, University Teacher, University of Sheffield, United Kingdom
 Dr David Hettle, Clinical Teaching Fellow, North Bristol NHS Trust, United Kingdom
 Dr David Wright, Chief Technology Officer, Kuano, United Kingdom
 Dr Debapriya Bhattacharya, Assistant Professor, Siksha 'O' An United States of America
 dhan University, India; Dr Deependra Hamal, Lecturer, Manipal College of Medical Sciences Nepal, Nepal; Dr Deepthi Vijay, Assistant Professor, Kerala Veterinary and Animal Sciences University, India; Dr Dickson Aruhom United Kingdom
 mama, PhD Fellow/Graduate Fellow, Makerere University, Uganda; Dr Dina Hetata, Clinical Microbiology Acting Senior Registrar, Jaber Al Ahmad Armed Forces Hospital Kuwait, Kuwait; Dr Durgadas Naik, Associate Professor of Medical Microbiology, Management and Science University Malaysia; Dr Eileen Sweeney, Infectious Diseases SpR, Trinity College, Ireland; Dr Ekindayo Cyrus Temitope, Researcher, University of Fort Hare, South Africa; Dr Elaine Cameron, Lecturer in Health Psychology, University of Stirling, United Kingdom
 Dr Elizabeth Cross, Infectious Diseases & Medical Microbiology Specialty Registrar, Western Sussex Hospitals NHS Foundation Trust, United Kingdom
 Dr Elizabeth Francis, Deputy Chief Pharmacist, Berkshire Healthcare NHS Trust, United Kingdom
 Dr Emily Rooney, Clinical Education Fellow in Infectious Diseases, Manchester Foundation Trust - Wythenshawe Hospital, United Kingdom
 Dr Emma Anne Murphy, Postdoctoral Research Scientist, Oxford University, United Kingdom
 Dr Enas Al-Ani, Postdoctoral Research Assistant, University of Wolverhampton, United Kingdom
 Dr Esther Njoki Maina, Senior Lecturer, University of Nairobi Kenya, Kenya; Dr Eunice Ngozi Anaele, Research Fellow, University of Nigeria, Nigeria; Dr Eva Krockow, Lecturer, University of Leicester, United Kingdom
 Dr Fahed Shadhab Bangash, MTI, Hull University Teaching Hospitals NHS Trust, United Kingdom
 Dr Felicity Alcock, Postdoctoral Research Associate, Newcastle University, United Kingdom
 Dr Felix Lankester, Assistant Professor & Director of Rabies Free Tanzania, Washington State University, United States of America; Dr Fintan Kelleher, Lecturer in Chemistry/Principal Investigator, Technological University Dublin, Ireland; Dr Florie Magalie Desriac, Researcher and Lecturer, Université de Caen, France; Dr Freya Harrison, Associate Professor, University of Warwick, United Kingdom, Dr Gayathri Lal, Research Scholar, ICAR-National Dairy Research Institute, India, Dr Gemma Wheldon, Consultant Microbiologist, Sheffield Teaching Hospitals, United Kingdom, Dr George Szonyi, Geriatrician, Sydney Local Health District, Australia; Dr George Thomas Williams, Postdoctoral Research Associate, University of Kent, United Kingdom; Dr Georgina Beckley, Trainee Microbiologist, North Bristol Trust, United Kingdom; Dr Gilbert Vergara, Microbiologist, South Cotabato Provincial Hospital, Philippines; Dr Glenn Q. Lees, Associate Veterinarian, Animal House Veterinary Hospital and Grooming Center, Philippines; Dr Greg Kowald, Clinical Sales & Technical Support, Associates of Cape Cod Int Inc, United Kingdom, Dr Gwennan Llwyd Jones, Microbiology ST4, Public Health Wales, United Kingdom; Dr Hala Mohamed Albahar Elhilali, Pharmacist, Elhilali Pharmacies, Sudan; Dr Hani Khuffash, General Practitioner Doctor, Ministry of Health, Palestine; Dr Harisree Paramel Nair, Postdoctoral Researcher, Anglia Ruskin University, United Kingdom; Dr Harsha Perera, Microbiologist, Public Health Wales, United Kingdom; Dr Harshal Parikh, Consultant Microbiologist, Wockhardt Hospitals Limited, India; Dr Helen Dillon, Consultant in Infectious Diseases & Acute Medicine, South Warwickshire FT, United Kingdom; Dr Hend Ibrahim, Inpatient Pharmacy Manager, Dar Alfouad Hospital, Egypt; Dr Hozaifa Elsayah, Clinical Pharmacist, Elaraby Hospital, Egypt; Dr Hudson Guyver, Internal Medicine Trainee, Norfolk and Norwich University Hospital, United Kingdom; Dr Huina Yang, Microbiologist, Royal Papworth Hospital NHS Foundation Trust, United Kingdom; Dr Ibrahim Kamara, Antimicrobial Resistance Operational Research Fellow, World Health Organization, Sierra Leonean; Dr Ibrahim Yusuf, Academic Staff/Researcher, Bayero University, Kenya; Dr Ifunanya Onw, Optometrist, Gwarimpa General Hospital, Nigeria; Dr Ikwelle Obiora Christian, Medical Officer, Nigerian Army School of Signals, Nigeria; Dr Ines Leonor Maciel Leitao Ferraz, Infectious Diseases Registrar, CHULN - Hospital Santa Maria, Portugal; Dr Ingrid Von Der Osten, Deputy Chief Physician of ICU, Venezuelan Institute of Social Security, Venezuela; Dr Ioannis Kopsidas, Infection Preventionist - Research Associate, Collaborative Centre for Clinical Epidemiology and Outcomes Research, Egypt; Dr Irfan Sha United Kingdom, ST3 Infectious Diseases and Microbiology, University Hospital North Midlands, United Kingdom; Dr Isaac Adesina, Lecturer, University of Medical Sciences Ondo City, Nigeria; Dr Ivan Palagin, Assistant Professor, Smolensk State Medical University, Russia; Dr Jaimini Gohil, Chief Pharmacist, The Aga Khan University Hospital Nairobi, Kenya; Dr James Whitehorn, Consultant in Microbiology and Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, United Kingdom; Dr Jasbir Singh Bedi, Associate Professor, Guru Angad Dev Veterinary and Animal Sciences University, India; Dr Jeet Moktan, Clinical Pharmacist, Adichunchanagiri University, India; Dr Jenny Herbert, Research Associate, University of Liverpool, United Kingdom; Dr Jess Vergis, Assistant Professor, Kerala Veterinary and Animal Sciences University, India; Dr Jill Hines Bennett, Medical Science Liaison Director, Spero Therapeutics, United States of America; Dr Joanne Foulkes, Senior Lecturer in Virology and Microbiology, Liverpool John Moores University, United Kingdom; Dr Johnathon Mills, Locum Consultant Microbiologist, NHS & University of Cambridge, United Kingdom; Dr Jorge Abarca, Infectious Disease Consultant, Bradford Teaching Hospital, United Kingdom; Dr Joseph Fadare, Associate Professor in Clinical Pharmacology and Therapeutics/Consultant Physician, Ekiti State University College of Medicine; Dr Joy Amina Mike Opara, Lecturer / Head of Department, Edo State Government Ministry of Health, Nigeria; Dr Juliet Elvy, Clinical Microbiologist, Wellington SCL, New Zealand; Dr Kalyani Borde, Assistant Professor, Apollo Institute of Medical Sciences and Research, India; Dr Karina O'Connell, Consultant Microbiologist, Beaumont Hospital Dublin, Ireland; Dr Katharine Cartwright, Consultant Physician Infectious Diseases, Sheffield Teaching Hospitals NHS FT,

United Kingdom; Dr Katie Fong, Consultant Microbiologist, Belfast Health & Social Care Trust, Northern Ireland; Dr Katie Sealey, Post Doctoral Researcher, Plymouth University, United Kingdom; Dr Kerrie Davies, Principal Clinical Scientist and Visiting Research Fellow, Leeds Teaching Hospitals NHS Trust and University of Leeds, United Kingdom; Dr Kevin Messters, Clinical Fellow in Paediatric Infectious Diseases, Evelina London Children's Hospital, United Kingdom; Dr Khaked Abdullah Alqurashi, Doctor/ Medical Resident, King Faisal medical complex Ministry of Health Saudi Arabia, Saudi Arabia; Dr Khizer Hayat, Doctor, Pet Center UVAS Lahore, Pakistan; Dr Khuen Foong Ng, Paediatric Infectious Disease Trainee, Bristol Royal Hospital for Children, United Kingdom; Dr Kumari Nisha, Senior Research Associate, Tar United States of Americakha, India; Dr Lasantha Rajakaruna Wijewardena Mudalige, Clinical Fellow in Medical Microbiology, Kings College Hospital, United Kingdom; Dr Latha Chattothayil, Professor and Registrar, Kerala Veterinary and Animal Sciences University, India; Dr Laura Alejandra Mora Moreo, Research Physician, Organizacion Clinica General del Norte, Colombia; Dr Laura Loughlin, Consultant Microbiologist, Belfast Health and Social Care Trust, Northern Ireland; Dr Leslie Root, Physician, Internal Medicine Specialist, Legacy Health in Portland, United States of America; Dr Linzy Elton, Postdoctoral Research Associate, University College London, United Kingdom; Dr Lucy Jefferson, Paediatrician, Bristol Children's Hospital, United Kingdom; Dr Luis Silva Lagos, Postdoc, University Medical Center Groningen, Netherlands; Dr Luria Founoi, Head of Research, CEDBCAM Medical Centre, Cameroon; Dr Mahwish Jawaid, Registrar Microbiology, Ministry of Health KSA, Saudi Arabia; Dr Maire Bedgley, Lecturer and Principal Investigator, Cork Institute of Technology, Ireland; Dr Mairi Macleod, Consultant Microbiologist, NHS Greater Glasgow and Clyde, United Kingdom; Dr Manjula Meda, Consultant Clinical Microbiologist and Infection Control Doctor, Frimley Health Foundation NHS Trust, United Kingdom; Dr Manu Raj Mathur, Senior Lecturer, University of Liverpool, United Kingdom; Dr Marco Haenssger, Assistant Professor in Global Sustainable Development, University of Warwick, United Kingdom; Dr Margherita Bertuzzi, Lecturer in Molecular Microbiology, University of Manchester, United Kingdom; Dr Mariam Ibrahim Nabeh, Veterinarian, Faculty of Veterinary Medicine Cairo University, Egypt; Dr Marianneta Chatzopoulou, Consultant in Clinical Microbiology, Larissa General Hospital, Greece; Dr Marios Josephidou, Medical Director, Peachy Health Lifestyle Clinic, United Kingdom; Dr Mariya Molai, Infectious Diseases Registrar, Hull University Trust, United Kingdom; Dr Mark Zak, Sr Medicinal Chemist, Walter Reed Army Institute of Experimental Therapeutics, United States of America; Dr Mary Varghese, Specialty Doctor in Microbiology, Poole NHS trust, United Kingdom; Dr Mathilde Chamula, Infectious Disease and Medical Microbiology Consultant, Centre hospitalier universitaire de Québec, Canada; Dr Maximilian Mauritz, Physician, Kinderklinik Datteln, Germany; Dr Milada Tavodova, Consultant Microbiologist, Pinderfields Hospital, United Kingdom; Dr Mohammed Manga, Reader and Consultant Clinical Microbiologist, Gombe State University and Federal Teaching Hospital, Nigeria; Dr Mohammed Nour Elnour, Infectious Diseases and Microbiology Trainee, Norfolk and Norwich University Hospital, United Kingdom; Dr Mohammed Saeed Almadan, Consultant, King Fahd Hospital of the University / Imam Abdulrahman Bin Faisal University, Saudi Arabia; Dr Muhammad Asaduzzaman, PhD Research Fellow, University of Oslo, Norway; Dr Muhd Haziq Fikry Abdul Momin, Scientific Officer, Department of Laboratory Services Ministry of Health, Brunei Darussalam; Dr M United Kingdomesh Pasupuleti, Principal Scientist, CSIR-Central Drug Research Institute Lucknow India, India; Dr Nadeem Raja, Consultant Microbiologist, Southend Hospital, United Kingdom; Dr Naomi Thompson, Consultant Microbiologist, Chesterfield Royal Hospital, United Kingdom; Dr Natalya Romanivna Matkovska, Academic Researcher, Ivano-Frankivsk National Medical University, United Kingdom; Dr Natasha Rhys, Research Fellow, King's College London, United Kingdom; Dr Nazima Pathan, Univeristy Lecturer in Paediatric Critical Care, University of Cambridge, United Kingdom; Dr Nektarios Marmaras, Clinical Fellow in Microbiology, University Hospitals of Leicester, United Kingdom; Dr Nicholas Power, Clinical Fellow in Infectious Diseases and Aspergillosis, University Hospital South Manchester, United Kingdom; Dr Nida Mohammed Ali Wadi, Senior Lecturer Pharmacy, National University of Science and Technology, Pakistan; Dr Nikolaos Makrygiannis, Consultant Microbiologist, Public Health Wales, United Kingdom; Dr Nitin Pal Kalia, Visiting Fellow, CSIR-Indian Institute of Integrative Medicine, India; Dr Noella Maria Delia Pereira, Clinical Fellow - Paediatric Infectious Diseases, St Georges University Hospitals NHSFT, United Kingdom; Dr Nur Farhanah Saefuddin, Lecturer of Tropical Medicine and Infectious Diseases, Faculty of Medicine Diponegoro University, Indonesia; Dr Obed Kwabena Offe Amponsah, MPHIL Candidate, Clinical Pharmacy, Kwame Nkrumah University of Science and Technology, Ghana; Dr Olawale Olufemi Adelowo, Associate Professor, Environmental Microbiology, University of Ibadan Nigeria, Nigeria; Dr Ourania Kakisi, Consultant Microbiologist, Norfolk & Norwich University Hospital, United Kingdom; Dr Oyekola Abiri, Microbiology Speciality Doctor, Southend University Hospital NHSFT, United Kingdom; Dr Pankaj Dhaka, Assistant Professor, Guru Angad Dev Veterinary And Animal Sciences University, India; Dr Pat Rahman, Director, Tara Biologics Limited, United Kingdom; Dr Paul Higgins, Principal Investigator, University of Cologne, Germany; Dr Paul Lee, Senior Medical Assessor, MHRA, United Kingdom; Dr Peter L United Kingdome, Retired Senior Director Pharmaceutical R&D, Retired from Pfizer, United Kingdom; Dr Peter Mogyorosi, Ceo, Senior consultant, LC Innoconsult Ltd., Hungary; Dr Philemon Damilola Ayodele, Veterinary Officer, Ministry of Agriculture, Nigeria; Dr Phillip Aldridge, Senior Lecturer, Newcastle University, United Kingdom; Dr Prathamest Sawant, Clinical Pharmacist Practitioner, Rajiv Gandhi University of Health Science, Bangalore, India; Dr Preneshni Rochelle Naicker, Clinical Microbiologist, University of Cape Town / Lancet Laboratories, South Africa; Dr Prince Darko Agyapong, Clinical Research Fellow, Kintampo Health Research Centre, Ghana; Dr Prithwiraj Chakrabarti, Consultant Microbiologist, Milton Keynes University Hospital, United Kingdom; Dr Puja Gupta, Specialty Doctor, Norfolk and Norwich University Hospital NHS Trust, United Kingdom; Dr Puneet Mahajan, Consultant Non Invasive Cardiologist, Guru Nanak Dev Super Speciality Hospital, India; Dr Punyawee Dulyayaangkul, Research Associate, University of Bristol, United Kingdom; Dr Rachel Bousfield, Infectious Diseases and Microbiology SpR, Addenbrooke's Hospital, United Kingdom; Dr Radu Botgros, Scientific Officer, European Medicines Agency, The Netherlands; Dr Rakesh Verma, Chief Executive Officer, National Accreditation Board for

Hospitals & Healthcare providers (India) (NABH), India; Dr Ralph Schwiebert, Medical Microbiology Registrar, Leeds Teaching Hospitals, United Kingdom; Dr Raman Sardana, Head, Infection Prevention and Control; Senior Consultant and Head Microbiology; Advisor Academics, Laboratory Services, Indraprastha Apollo Hospitals IMCL; Dr Randa Bazzi, Veterinarian, Masters at Public health at the University of Debrecen, Hungary; Dr Raphael Ondondo, Health Scientist, CDC Global Health Kenya, Kenya; Dr Razan Saman, ST5, Leeds Teaching Hospitals NHS Trust, United Kingdom; Dr Rebecca Smith, SHO Medicine, ID Medical, United Kingdom; Dr Rhys Evans, Specialist Biomedical Scientist, Public Health Wales, United Kingdom; Dr Riccardo Giuntini, Locum Consultant in Acute Medicine, King's College Hospital NHS FT, United Kingdom; Dr Robert Jackson, Consultant Medical Microbiologist, Gloucestershire Hospitals NHS Foundation Trust, United Kingdom; Dr Romana Sarwar, Assistant Professor Zoology, Women University Swabi KPK Pakistan, Pakistan; Dr Rose Harrison, Speciality Registrar, Leeds Teaching Hospital, United Kingdom; Dr Ruth Radcliffe, Consultant Paediatrician, University Hospitals of Leicester, United Kingdom; Dr S Mephram, Consultant in Infection, Royal Free London NHS Trust, United Kingdom; Dr Sabeen Faraz, Clinical Fellow, Chelsea West Minister NHS Trust, United Kingdom; Dr Sabita Parida, Locum Consultant Clinical Microbiologist, Dorset County Hospital NHSFT, United Kingdom; Dr Salah Elshibly, Associate Specialist, Northern Health and Social Care, United Kingdom; Dr Sally Ager, Consultant Microbiologist, Leeds Teaching Hospitals NHS Trust, United Kingdom; Dr Salma Gayed, Spr, Addenbrookes Cambridge University Hospital, United Kingdom; Dr Samantha McLean, Senior Lecturer in Microbiology, Nottingham Trent University, United Kingdom; Dr Samuel Akpan, Programs Coordinator, One Health and Development Initiative, Nigeria; Dr Samuel Orubu, Post Doc Associate, Boston University, United States of America; Dr Sana Eijaz, Assistant Professor, Ph.D (Molecular Medicine), University of Karachi, Pakistan; Dr Sandeep Jayaseka, Registrar in Oral and Maxillofacial Surgery, Ministry of Health, Sri Lanka; Dr Sandeep Reddy, MSc Student, London School of Hygiene and Tropical Medicine, United Kingdom; Dr Sara Ali, Assistant Professor, International University of Africa, Sudan; Dr Sarah Logan, Consultant in Infectious Diseases, Hospital for Tropical Diseases, University College London, United Kingdom; Dr Sarah Stewart, Staff Clinician in Internal Medicine & Oncology, Royal Veterinary College University of London, United Kingdom; Dr Sejla Kotoric Keser, Specialist in Medical Microbiology, Institute for Public Health Canton Sarajevo, Bosnia and Herzegovina; Dr Seniyat Afegbua, Lecturer, Ahmadu Bello University, Nigeria; Dr Seth Kwabena Amponsah, Lecturer, University of Ghana, Ghana; Dr Seyed Mohammad Taghi Gharibzahedi, Research Leader in Food and Nutrition Sciences, University of Tehran, Iran; Dr Sharon Irvine, ID Consultant, The Royal Liverpool University Hospital, United Kingdom; Dr Sheetal Sundeep, Consultant Microbiologist, Northumbria Healthcare NHSFT, United Kingdom; Dr Sherifat Olayemi Balogun-Rajo, PhD Candidate - Veterinary Pharmacology, Usmanu Danfodio University, Nigeria; Dr Shini Edwin Samuel, General Duty Medical Officer, Central Government Health Scheme Ministry of Health & Family Welfare Government of India, India; Dr Shweta Singh, Research Associate, National University of Singapore, Singapore; Dr Simon Baines, Principal Lecturer Microbiology, University of Hertfordshire, United Kingdom; Dr Simon Patten, Consultant Acute Medicine, Royal Devon And Exeter Trust, United Kingdom; Dr Smruti Prakash Mishra, Postgraduate Student, Indian Institute of Public Health Gandhinagar, India; Dr Sophia De Saram, Specialist Registrar Microbiology and Infectious Diseases, North Middlesex University Hospitals NHS Trust, United Kingdom; Dr Stephen Ian Walimbwa, Clinical Trial Manager, Infectious Diseases Institute, Uganda; Dr Stineke Van Houte, Senior Fellow, University of Exeter, United Kingdom; Dr Stuart Kelly, Academic Skills Assistant, Calderdale College, United Kingdom; Dr Supram Hosuru Subramanya, Assistant Professor of Microbiology, Manipal College of Medical Sciences, Nepal; Dr Surekha Frith, Medical Director, Shionogi, United Kingdom; Dr S United States of American Awad Morsy, Lecturer, Faculty of Medicine Alexandria University Egypt, Egypt; Dr Suzanne Hocknell, Research Associate, Newcastle University, United Kingdom; Dr Syed Ahmed, Senior Lecturer & Head, Department of Pharmacy Practice, International Medical University (IMU), Malaysia; Dr Syed Badshah, Assistant Professor, Islamia College University Peshawar, Pakistan; Dr Tasnima Begum, FY1, University Hospitals of North Midlands NHS Trust, United Kingdom; Dr Thamarai Janganan, Lecturer in Microbiology, University of Bedfordshire, United Kingdom; Dr Thomas Ikech United Kingdomwu Odo, Veterinary Officer, Veterinary Services Department Agriculture and Rural Development Secretariat Federal Capital Territory Administration Abuja Nigeria, Nigeria; Dr Timothy Miles, ID Micro SpR, Imperial College London, United Kingdom; Dr Unell Barrington George Riley, Consultant Microbiologist, Royal Marsden NHSFT, United Kingdom; Dr Usman Abdulrahman, Physician, University of Abuja Teaching Hospital, Nigeria; Dr Vanessa Kuan Wong, Consultant in Microbiology and Infectious Diseases, Addenbrooke's Hospital Cambridge University Hospital NHS Foundation Trust, United Kingdom; Dr Victoria Austin, Pre-Reg Clinical Scientist, Ninewells Hospital and Medical School, United Kingdom; Dr Vincent Amarh, Post-Doctoral Fellow, CDC Global Health Kenya, Ghana; Dr Vinisha Malhotra, Pathologist, Government Medical College and Hospital, India; Dr Vipul R Nimavat, Assistant Professor, Anand Agricultural University, India; Dr Wafaa Abd El-Ghany, Professor Doctor, Cairo University, Egypt; Dr Waqas Ahmad, Assistant Professor, KBCMA University College of Veterinary and Animal Sciences Narowal Campus, Pakistan; Dr Wenjuan Cong, Research Fellow, University of Bristol, United Kingdom; Dr William Dibb, Consultant Infection Control Doctor (semi-retired), Graduated: University of Cambridge, United Kingdom; Dr Yara Mohsen Khalaf, Infectious Diseases Clinician, Joint Commission International Accredited Hospital, Egypt; Dr Yuri Antonio Diaz Fernandez, Senior Research Fellow, University of Liverpool, United Kingdom; Dr Zack Fang, Consultant Microbiologist, Medway NHS Foundation Trust, United Kingdom; Dr Zubair Ahmad Saidi, Clinical Pharmacist, Zubair Ahmad Saidi, Afghanistan; Evangelos Vryonis, Infectious Diseases Consultant, University Hospitals Coventry & Warwickshire, United Kingdom; Gopal Sharma, Medical Lab Technologist,

Swasthya Kalyan, India; Griselle Martinez, Veterinary Student, Royal Veterinary College, United Kingdom; Jaiza Samara Macena De Araujo, PhD Student, Piracicaba Dental School, Brazil; Lai Sheung Ma, Pharmacist, Oxford University Hospitals NHS Foundation Trust, United Kingdom; Miss Adepeju Kafayat Olowookere, Senior Medical Laboratory Scientist, LTHospital Ogbomoso, Nigeria; Miss Aliyah Undre, Antimicrobial Lead Pharmacist, NHS Harrow CCG, United Kingdom; Miss Amanda Daniel, Lead IPC Specialist, Public Health Wales, United Kingdom; Miss Amie Jobe, Antimicrobial Admin Assistant, Great Western Hospitals NHS Foundation Trust; Miss Amy White, OPAT Staff Nurse, South Warwickshire FT, United Kingdom; Miss Anisha Shah, Rotational Pharmacist - Antimicrobial, London North West University Healthcare NHS Trust, United Kingdom; Miss Ann Snaith, PhD Student, University of Birmingham, United Kingdom; Miss Annette Clarkson, Lead Pharmacist Antimicrobials and Infection control, Nottingham University Hospitals NHS Trust, United Kingdom; Miss Ayolola Eni-Olotu, Medical Student, Imperial College London, United Kingdom; Miss Bee Yean Ng, Specialist Antimicrobial Pharmacist, Buckinghamshire Healthcare NHS Trust, United Kingdom; Miss Bethan Eleri Thomas, Pharmacist, Swansea Bay University Health Board, United Kingdom; Miss Charley Bourner, Communications Executive, Page Medical, United Kingdom; Miss Cheyenne Jenna Thompson, Student, Anglia Ruskin University, United Kingdom; Miss Ching Fan, Pharmacist, Royal Berkshire Hospital, United Kingdom; Miss Cielito Moreno Arturo, Student, Universidad del Rosario, Colombia; Miss Elise Christina D'cunha, Trainee Clinical Scientist, University Hospitals Plymouth, United Kingdom; Miss Elisha Hughes, Biomedical Support Worker, Public Health Wales; Miss Emma Foster, Student, Royal Veterinary College, United Kingdom; Miss Hannah Gustafson, Manufacturing Technician, Thermofisher Scientific, United Kingdom; Miss Hasinaa Patel, Specialist Infectious Diseases Pharmacist, Guy's and St. Thomas' NHS FT; Miss Hayley Brown, Science Communications Executive, Page Medical, United Kingdom; Miss Hazel Forde, Rotational Pharmacist, Cambridge University Hospitals NHSFT, United Kingdom; Miss Heather Galloway, Lead Laboratory Microbiologist, Malawi-Liverpool-Wellcome Trust, Malawi; Miss Heather Thompson, Antimicrobial Pharmacist, NHS Lanarkshire, United Kingdom; Miss Helen McGowan, Antimicrobial Pharmacist, Croydon Health Services NHS Trust, United Kingdom; Miss Jade Conlon, Specialist Biomedical Scientist, Royal Bournemouth and Christchurch NHS FT, United Kingdom; Miss Jenna Davis, PhD Student, Loughborough University, United Kingdom; Miss Jennifer McClintick, Clinical Pharmacist, NHS Lanarkshire, United Kingdom; Miss Jenny Littler, PhD Student, University of Warwick, United Kingdom; Miss Joana Rodrigues, Associate Lecturer, Anglia Ruskin University, United Kingdom; Miss Kelly Parkin, PhD Student, Sheffield Hallam University, United Kingdom; Miss Kirsty Smitten, Postgraduate Researcher, University of Sheffield, United Kingdom; Miss Laura Seeney, Biomedical Student, University of Birmingham, United Kingdom; Miss Liliana Lopes, Specialist Biomedical Scientist, Poole Hospital NHSFT, United Kingdom; Miss Lucy Chambers, PhD student, Manchester Metropolitan University, United Kingdom; Miss Marianna Muszynska, Biomedicine Student, Birkbeck College, United Kingdom; Miss Mollie Joyce, PhD Student Astromedicine and Astropharmacy, University of Nottingham, United Kingdom; Miss Natalia Skeen, Project Officer, University of Warwick, United Kingdom; Miss Niamh Harrington, PhD Student, University of Warwick, United Kingdom; Miss Nicolette Graham, Clinical Pharmacist Lead - AMS, Queensland Children's Hospital, Australia; Miss Nikol Kaderabkova, PhD Student, Imperial College London, United Kingdom; Miss Rachel Page, Teacher, Nethergate Academy, United Kingdom; Miss Samantha Henry, PhD Research Student, ISMB Research Lab Birkbeck University of London, United Kingdom; Miss Sarah Bristoll, Clinical Services Manager / OPAT Nurse, Healthcare at Home, United Kingdom; Miss Sarah Butler, IV Therapies Clinical Lead, Lloyds Pharmacy Clinical Homecare, United Kingdom; Miss Shama Hamal, Doctor CT3, Plymouth Hospitals NHST, United Kingdom; Miss Sreelekshmi Surendran, Biomedical Sciences Student, Middlesex University London, United Kingdom; Miss Tanzina Islam, Academic Administrator and Examinations Officer, Nelson College London, United Kingdom; Miss WanYee Lee, Antimicrobial Lead Pharmacist, East and North Hertfordshire Trust, United Kingdom; Miss Zainab Tiamiyu, Student, Federal University Dutsin-ma Nigeria and Katsina, Nigeria; Mr A P Mohandas, Physiotherapist, Svasti Physiotherapy and Speech Therapy Center, India; Mr Aaron Alejandro, PhD Student, Murdoch University, Australia; Mr Abbas Abel Anzaku, Program Officer, Clinical Laboratory Scientist, Institute of Human Virology Nigeria, Nigeria; Mr Abdulakeem Adams, Public Health Research Associate, EpidAlert Informative Initiative, Nigeria; Mr Abdulrazak Sale Yusuf, Medical Laboratory Technician, MGK Healthcare Limited, Nigeria; Mr Adamu Muhammad Ibrahim, Medical Laboratory Scientist, Jigawa Ministry of Health, Nigeria; Mr Adedamola Adenekan, Graduate Student, Federal University of Agriculture Abeokuta, Nigeria; Mr Adel Sheikh, Antibiotic Pharmacist, Portsmouth Hospitals University Trust, United Kingdom; Mr Adeshola Adebayo Fagbemi, Research Assistant, Postgraduate College University of Ibadan, Nigeria; Mr Ambanibe Akeneck Jerome, Clinical Researcher, Association of Orphans and the Disabled ASODI-Cameroon., Cameroon; Mr Andrew Hanton, MSc Student, The University of Edinburgh, United Kingdom; Mr Andrew Platten, Market Access Manager, United Kingdom and Ireland, Becton Dickinson, United Kingdom; Mr Apon Paul, Student Biotechnology, Islamic University, Uganda; Mr Ayodele Adedokun, Student, Usmanu Danfodiyo University, Nigeria; Mr Bashiru Eya Sani, Lecturer, Federal University of Lafia, Nigeria; Mr Brian Matovu, Postgraduate Student, Makerere University, Uganda; Mr Charles Benjamin Middleton, Human Biology and Infectious Diseases, University of Salford, United Kingdom; Mr Charles Cooper, Masters Student, University of Oxford, United Kingdom; Mr Chris Winnard, Principal Pharmacist, Sheffield Teaching Hospitals, United Kingdom; Mr Christian Edache Ochigbo, Graduate Intern, National Veterinary Research Institute, Nigeria; Mr Christopher Oladimeji Fakorede, Research Assistant, Tropical Laboratories, Nigeria; Mr Ch United Kingdomwuemeka Eric Alozie, Masters Student, University of Bath, United Kingdom; Mr Cliff Whitefoot, Retired Co-Founder, Aspergillus Trust, United Kingdom; Mr Colin Larkworthy, Clinical Trials Support Officer, University of Oxford, United Kingdom; Mr Connor Field, Student, Anglia Ruskin University, United Kingdom; Mr Daniel Ajayi, Student, University of Lagos College of Medicine, Nigeria; Mr Daniel Brant, Senior Staff Nurse Acute Care at Home, Cornwall Partnership NHS Trust, United Kingdom; Mr David Hilbert, Lead Pharmacist Antimicrobials, Western Sussex Hospitals NHS Foundation Trust, United Kingdom; Mr David Smith,

Lead Antimicrobial Pharmacist, Lewisham and Greenwich NHS Trust, United Kingdom; Mr Dominic Wen Shun Chan, Researcher & Discovery Consultant, National Defense University of Malaysia, Malaysia; Mr Ed Whittaker, Medical Student, University of Edinburgh, United Kingdom; Mr Emelie Anekwu, Principal Physiotherapist, Alex Ekwueme Federal University Teaching Hospital, Nigeria; Mr Feranmi Obe, Student Medical Laboratory Sciences, Ladoko Akintola University of Technology, Nigeria; Mr Gafar Bamigbade, Fellow, Teach for Nigeria, Nigeria; Mr George Kirke, Research Assistant, Brunel University London, United Kingdom; Mr Greater K. Oyejobi, Lecturer and PhD Student in Microbiology, Osun State University, Nigeria; Mr Gurjinder Bains, EU Medical Information Scientist, Shionogi, United Kingdom; Mr Gyles Wren, Medical Science Liaison, Advanz Pharma, United Kingdom; Mr Habeeb Rahman, PhD Student, Kalinga Institute of Industrial Technology University India, India; Mr Hamid ur Rahman, Lecturer, University of Swat, Pakistan; Mr Hiu Leung, Lead Antimicrobial Pharmacist, Lewisham and Greenwich NHS Trust, United Kingdom; Mr Ignatius Weru Irimu, Research Intern, Kenya Medical Research Institute, Kenya; Mr Ivan Mugeni, Masters Student, AU-Safe Fish Uganda, Uganda; Mr Iyiola Olatunji Oladunjoye, Medical Student, University of Ilorin, Nigeria; Mr James Butler, PhD Researcher, University of Plymouth, United Kingdom; Mr James Cunningham, Business Development Manager, Vygon, United Kingdom; Mr James Ryan, Section Lead/Senior Biomedical Scientist, Salisbury NHS Foundation Trust, United Kingdom; Mr Jhon Wilson Alcantara Antido, Medical Microbiology Student, University of the Philippines, Philippines; Mr Jihad Hameed Ahmed, Medicative Nurse, Sirwany nwe Sports Club, Iraq; Mr Jonathan Jato, Assitant Lecturer, University of Health and Allied Sciences, Ghana; Mr Jose Ligat Tambuyat, Pharmacist, Farmacia Solonio, Philippines; Mr Kamrul Hassan Suman, Research Assistant, Bangabandhu Sheikh Mujibur Rahaman Agricultural University (BSMRAU), Bangladesh; Mr Kamrul Hassan Suman, Research Associate, Environmental and Aquatic Biology Research Group, Bangladesh; Mr Kaushik Mitra, Proprietor, Chandigarh University Graduate, India; Mr Kayode Owoyemi, Postgraduate Researcher, Ajayi Crowther University School of Post Graduate University, Nigeria; Mr Khem Sharma, Sub-Inspector, Central Police Forensic Science Laboratory, Nepal; Mr Lawrence Irimiya Mafulul, Senior Regulatory Officer, National Agency for Food and Drug Administration and Control, Nigeria; Mr Lubem Agbendeh, Public Health Student, BRAC University Bangladesh, Bangladesh; Mr Mario Lungolov, Biomedical Science Student, University of Westminster, United Kingdom; Mr Matthew Cudden, Laboratory Technician, Bishop Burton College, United Kingdom; Mr Matthew O'Dwyer, Section Lead/Training Lead, Universtity Hospitals Southampton, United Kingdom; Mr Michael Scullin, Pharmacist, South Eastern Health and Social Care Trust, United Kingdom; Mr Mohamed Elsayed Faro United Kingdom Mostafa, Microbiologist, Al-Azhar University, Egypt; Mr Muhammad Younis Dahar, Consultant Medical Microbiologist, Gloucestershire Hospitals NHS Foundation Trust, United Kingdom; Mr M United Kingdom maila Adegbenga Isiaka, Student, Lagos State University Ojo, Nigeria; Mr Mwalimu Kingunge, Senior Medical Laboratory Technologist, Tawfiq Hospital Malindi, Kenya; Mr Onyekachi Onyekwere, Scientific Officer, National Biotechnology Development Agency, Nigeria; Mr Ori Solomon, Graduate of Global Health, ISGlobal Barcelona, University of Barcelona, Spain; Mr Paul Aimua, PhD(c) in Life Science, Keele University, United Kingdom; Mr Paul Owolabi, Laboratory Assistant, Obafemi Awolowo University, Nigeria; Mr Paul Wade, Consultant Pharmacist (Infectious Diseases), Guy's St. Thomas' NHS Foundation Trust, United Kingdom; Mr Pelumi Adewole, Assistant Lecturer, Kwara State University Malete, Nigeria; Mr Precious Obioha Owuamalam, PhD Student, University of Birmingham, United Kingdom; Mr Prijay Hitesh Bakrania, Resident Pharmacist, Guy's and St Thomas' NHS Foundation Trust, United Kingdom; Mr Rabiul Abdulwanhab, Scientific Officer, Bauchi State Agency for the Control of HIV/AIDS Tuberculosis/Leprosy and Malaria (BACATMA), Nigeria; Mr Ramiz Amin, Antibiotic Pharmacist, The Hillingdon Hospitals NHS Foundation Trust, United Kingdom; Mr Rashedul Islam, Medical Laboratory Technologist, Khwaja Yunus Ali University, Bangladesh; Mr Rob Moule, OPAT Specialist Support Nurse, Addenbrookes Hospital, United Kingdom; Mr Rohul Amin, Undergraduate Student of Doctor of Veterinary Medicine, Bangabandhu Sheikh Mujibur Rahman Agricultural University, Bangladesh; Mr Ryan Campbell, Student, University of London Institute Paris, France; Mr S Srinivasan, Ph.D Scholar, Presidency College Chennai, India; Mr Sajal Saha, PhD Candidate, Monash University, Australia; Mr Salami Habeeb, Student Researcher, Ladoko Akintola University of Technology, Nigeria; Mr Salih Ahmed Aladeh, Regulatory Officer, National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria; Mr Sambo Obadiah Elkanah, Associate Professor, Taraba State University, Nigeria; Mr Samson Charles, Graduate Biochemistry, University of Bath, United Kingdom; Mr Samuel Chatten, Pharmacist, Maidstone and Tunbridge Wells NHS Trust, United Kingdom; Mr Saravanan Kotteeswaran, Researcher, International Youth Research Foundation, India; Mr Shahid Chowdhury, Specialist Pharmacist in Surgery & Intensive Care, Kettering General Hospital, United Kingdom; Mr Shahzad Razaq, Principal Pharmacist, Heartlands Hospital, United Kingdom; Mr Shamsudeen Dahiru Kankara, Teacher, State Universal Basic Education Board, Kaduna State Government, Nigeria; Mr Shobith Suresh, Virology Student, Kannur University, India; Mr Stephen Segun David, Consultant, Oriflame, United Kingdom; Mr Steven Kakooza, Public Health Specialist, Vétérinaires Sans Frontières Germany, Kenya; Mr Stylianos Karanastasis, Medical Laboratory Assistant - Haematology, Dartford Gravesham NHS Trust, United Kingdom; Mr Taiwo Oladele Popoola, Chief Microbiologist [Manager], Emor Pharmaceutical Industries Limited, Nigeria; Mr Tarun Singh, AP-PharmD, Maharishi Markandeshwar (Demmed to be University), India; Mr Toby Stock, Operational Manager, Mid Essex Hospital Trust, United Kingdom; Mr Tolulope Folaranmi, Specialist Biomedical Scientist, Leeds Teaching Hospitals NHS Trust, United Kingdom; Mr Valerii Chmut, Associate Professor, Department of Dermatology and Venereology, Ivano-Frankivsk National Medical University, United Kingdom; Mr Veselin Dimitrov, Chief Pharmacist, Lexon United Kingdom, United Kingdom; Mr Victor Kouassi, Scientific Affairs Officer, Global Antibiotic RD Partnership,

Switzerland; Mr Victor Udoka Jibunor, Graduate Research Assistant, Ahmadu Bello University, Nigeria; Mr Victor Wogu, Public Health, University of Benin, Nigeria; Mr Wisdom Mashiri, Anatomy Demonstrator, University of Zimbabwe, Zimbabwe; Mr Xavier Khan, PhD Researcher, University of Reading, United Kingdom; Mr Yusuf Olalekan Babatunde, Student, Non-governmental organization at Nigeria AIDES, Nigeria; Mr Yves Chan, Student Medicine, Zhujing Hospital, China; Mrs Ainsley Fraites, Homecare Nurse, Healthcare at Home, United Kingdom; Mrs Anna Maruta, IPC/AMR Lead, World Health Organisation, Sierra Leone; Mrs Carleen Hibberd, Lead Antimicrobial Pharmacist, South Eastern Health and Social Care Trust, United Kingdom; Mrs Donna Chaplin, Lead Nurse for IV therapy, Royal Surrey NHS Foundation Trust, United Kingdom; Mrs Donna Johnson, MSc Course Director, Biomedical Sciences, Leeds Beckett University, United Kingdom; Mrs Duaa Ahmad, Lead Pharmacist Antimicrobial Stewardship, Mid Yorkshire NHS Trust, United Kingdom; Mrs Elizabeth Stokle, Independent Consultant Antimicrobial Resistance & Infection Prevention, Self-Employed - WHO Europe, United Kingdom; Mrs Emma Walton, Specialist Pharmacist, Taunton & Somerset NHS FT, United Kingdom; Mrs Esperanza Palenzuela, Pharmacist, NHS Lothian, United Kingdom; Mrs Eunice Folusho Akinleye, Medical Laboratory Scientist, Isolo General Hospital, Nigeria; Mrs Ezinne Aniето, Student, Nnamdi Azikiwe University Awka, Nigeria; Mrs Fiona Nadin, Clinical Nurse Specialist Outpatient Antimicrobial Therapy, Frimley Health NHS Foundation Trust, United Kingdom; Mrs Fiona Throp, Community Advanced Practitioner, Airedale NHSFT, United Kingdom; Mrs Gabrielle Scott, Specialist Biomedical Scientist, Barking Havering and Redbridge University Hospitals NHS Trust, United Kingdom; Mrs Gail Sweeney, Staff Nurse, South Warwickshire NHSFT, United Kingdom; Mrs Ifeoluwa Akanni, Pharmacist, Nwafor Pharmacy, Nigeria; Mrs Jacqueline Fox, Professional Lead Nurse, NHS Lanarkshire, United Kingdom; Mrs Jacqueline Slater, Senior Sister, Sandwell and West Birmingham NHS Trust, United Kingdom; Mrs Joanna Coles, Consultant (retired), Retired, previous NHS employee, United Kingdom; Mrs Julie Nile, Clinical Sister, South Tees Foundation Trust, United Kingdom; Mrs Julie Statham, Principal Pharmacist for infection. OPAT team manager, South Warwickshire NHS FT, United Kingdom; Mrs Kate Herbert, Administrator, Dorchester Abbey, United Kingdom; Mrs Kim Hogg, Primary Care Coordinator, Spectrum Community Services, United Kingdom; Mrs Kirstin Khonyongwa, Deputy Head of Infection Surveillance, King's College Hospital, United Kingdom; Mrs Laura Jane McGlinchey, Infection Prevention and Control Specialist, University of Essex, United Kingdom; Mrs Lesley Hughes, Case Load Holder, Student District Nurse, Betsi Cadwalader Local Health Board, United Kingdom; Mrs Linh Dao, Front of House, PHO Restaurant Birmingham, United Kingdom; Mrs Louise Campbell, Pharmacist, Northern Health and Social Care Trust, United Kingdom; Mrs Louise Nicholson, Lead Pharmacist - OPAT, Royal Surrey Hospital, United Kingdom; Mrs Madga Phipps, Specialist Biomedical Scientist, Gloucestershire Hospitals NHSFT, United Kingdom; Mrs Mandeep Dhaliwal, Specialist Biomedical Scientist, Berkshire and Surrey Pathology Services, United Kingdom; Mrs Mary Virdee, Antimicrobial Pharmacist, Royal Shrewsbury and Telford NHS Trust, United Kingdom; Mrs Nicola Robinson, Antimicrobial Pharmacist, Kingston Hospital NHSFT, United Kingdom; Mrs Nicole Britten, Master by Research Student, Manchester Metropolitan University, United Kingdom; Mrs Nnenna Victoria Ezugwu, Medical Laboratory Scientist, Nnamdi Azikiwe University Teaching Hospital Nnewi, Nigeria; Mrs Oluwatobi Bamidele, Medical Laboratory Scientist, University of Ibadan, Nigeria; Mrs Ratna Yuliani, Lecturer, Universitas Muhammadiyah Surakarta, Indonesia; Mrs Rebecca Walker, Senior Sister, Northamptonshire Healthcare NHSFT, United Kingdom; Mrs Rebecca Warwick, Medical Science Liaison, Menarini, United Kingdom; Mrs Reem Al-Shidhani, PhD Student, University of Manchester, United Kingdom; Mrs Sarah Kelly, Nurse Practitioner, Swansea Bay NHS Trust, United Kingdom; Mrs Seny Sunny, Biomedical Scientist, Epsom and St Helier University Hospitals NHS Trust, United Kingdom; Mrs Theopista Lotto, Research Scientist, Ifakara Health Institute, Tanzania; Mrs Tolu Akinrjumu, Antimicrobial Pharmacist, Medway NHS Foundation Trust, United Kingdom; Ms Adele Batrouney, Pharmacist, Austin Hospital, Australia; Ms Alba Altet, OPAT Specialist Nurse, Royal Victoria Infirmary, United Kingdom; Ms Ana Patricio, Antimicrobial Pharmacist, East and North Hertfordshire Trust, United Kingdom; Ms Ana Serrato, Veterinarian, San Patricio Médicos Veterinarios Especialistas, Mexico; Ms Anais Essilini, PhD Student, Université de Lorraine, France; Ms Anju Vt, PhD Student Biochemistry and Molecular Biology, Pondicherry University, India; Ms Anne Amulele, PhD Student, KEMRI Wellcome Trust, Kenya; Ms Arooba Elahi, Dentist, JP Medical Care, United Kingdom; Ms Barbara Allen, Pharmacist, Northern Health and Social Care Trust, United Kingdom; Ms Carly Ching, Researcher, Boston University, United States of America; Ms Carolina Rivera, Microbiology Student, Colegio Mayor de Cundinamarca University, Colombia; Ms Cassandra Edwards, MSc Medical Microbiology, University of Manchester, United Kingdom; Ms Cecilia Drapeau, Clinical Fellow (Trainee) Microbiology, King's College Hospital, United Kingdom; Ms Claire Beesley, PhD Student, Nottingham University, United Kingdom; Ms Eleni Koursari, Masters Student, The University of Sheffield, United Kingdom; Ms Elizabeth Cummins, PhD Student, University of Birmingham, United Kingdom; Ms Elizabeth Odonnell, CNS OPAT, Guys and St. Thomas NHS Trust, United Kingdom; Ms Elizabeth Palmer, Australian Public Service Officer, Department of Defence, Australia; Ms Emily Procter, Scientific Communications Executive, Page Medical, United Kingdom; Ms Emma Henderson, Infectious Disease Pharmacist, Hutt Valley District Health Board, New Zealand; Ms Estelle Mbadiwe, Founding Partner National Action Plan AMR, Ducit Blue Solutions, Nigeria; Ms Gayle Anderson, Specialist Pharmacist, NHS Grampian, United Kingdom; Ms Ghaidaa Alharthi, Clinical Pharmacy Student, Taif University, Saudi Arabia; Ms Gillian Kiely, Antimicrobial Pharmacist, The Royal Marsden NHS Foundation Trust, United Kingdom; Ms Imogen Shaw, Assistant Healthcare Scientist, Public Health England, United Kingdom; Ms Iryna De Jesus Andrade, Specialist Healthcare Scientist, Great Ormond Street Hospital, United Kingdom; Ms Jessa Turreda, University Research Associate, University of the Philippines Manila, Philippines; Ms Jo Moore, Medical Information Operations Manager, Shionogi B.V, United Kingdom; Ms Judith Nwatu, Public Health Master Student, Hamburg University of Applied Sciences-Haw Hamburg Germany, Germany; Ms Kathleen Moloney-Omar, Hospital Scientist, The New South Wales Ministry of Health, Australia; Ms Kathy Gillespie, Antimicrobial Pharmacist, The Newcastle Upon Tyne Hospitals NHS FT, United Kingdom; Ms Kirsty Harvey, Medical

Microbiology Registrar, University Hospital Leicester, United Kingdom; Ms Lindsey Edwards, Veterinary Surgeon, Woodview Veterinary Clinic, United Kingdom; Ms Louise Delany, Antimicrobial Pharmacist, National Maternity Hospital Ireland, Ireland; Ms Lucy Kelly, PhD Student, University of Warwick, United Kingdom; Ms Malaz Zaki Aldeen Ahmed Alfadl, Student, Neelain University, Sudan; Ms Maria Jose Durarte Aguilera, Microbiologist, University of Melbourne, Australia; Ms Marian Voloshynovych, Associated Professor, Ivano-Frankivsk National Medical University, United Kingdom; Ms Mercy Omuero Edejechwro, Research Officer, University of Benin, Nigeria; Ms Moussumi Shyam, Doctoral Research Candidate, Birla Institute of Technology, India; Ms Oghenerobo Esieboma, Pharmacist, St Nicholas Hospital, Nigeria; Ms Oonagh Mccourt, Antimicrobial/OPAT Pharmacist, Northern Health and Social Care Trust, United Kingdom; Ms P Saravana Kumari, Associate Professor, Rathnavel Subramaniam College of Arts and Science , India; Ms Pauwels Pauwels, PhD Researcher, University of Antwerp, Belgium; Ms Phillipa Burns, Trainee Consultant Clinical Scientist, Hull University Teaching Hospitals, United Kingdom; Ms Poonum Wilkhu, Clinical Pharmacist , Buckinghamshire New University, United Kingdom; Ms Rashmi Karki, Medical Laboratory Scientist, National Public Health Laboratory, Nepal; Ms Rhiannon Lyon, PhD Student, University of Warwick, United Kingdom; Ms Ruth Mcaleer, Lead Antimicrobial Pharmacist, Cardiff and Vale University Health Board, United Kingdom; Ms Sabrina O'Regan, Pharmacist, HSE West, United Kingdom; Ms Silpi Sarkar, Assistant Professor, Vignan's Foundation For Science Technology and Research, India; Ms Sree Vandana Yerramsetty, Molecular Geneticist, Shanmugha Arts, Science, Technology & Reserch Academy, India; Ms Stephanie Hutchings, Trainee Clinical Scientist, Public Health England, United Kingdom; Ms Suellen Rodrigues, Medical Science Liaison Manager, Merck & Co (MSD), Brazil; Ms S United States of American Mutua, Chief Pharmacist, Gertrude's Children's Hospital, Kenya; Ms Tara Levano-Osores, Mrs Global Infectious Diseases Student, Birbeck University of London, United Kingdom; Ms Temitope Olajide, Pharmacy Intern, Yaba Neuropsychiatric Hospital, Nigeria; Ms Tessia Evenor, Specialist Biomedical Scientist, Norfolk and Norwich University Hospital, United Kingdom; Ms Theresa Awotundun, Researcher, Ajayi Crowther University , Nigeria; Ms Therese Reyes Suratos, Medical Technologist, Philippine Heart Center, Philippines; Ms Uma Arumugam, Student, SRM College of Pharmacy, India; Ms Yee Yee Hor, Clinical Pharmacist, Ministry of Health, Malaysia; Pharmacist Amachi Emenike, Community Pharmacist, Pillzone Healthcare Ltd, Nigeria; Professor Celine Pulcini, Infectious Diseases Professor, Universite de Lorraine, France; Professor Elizabeth Vera, Professor, EDP University, Puerto Rico; Professor Kennedy Foinku Chah, Teaching and Research, University of Nigeria, Nigeria; Professor Mark Holmes, Professor of Microbial Genomics, University of Cambridge, United Kingdom; Professor Michael Brockhurst, Professor of Evolutionary Microbiology; Professor Min Yue, Professor, Zhejiang University, China; Professor Nicholas Feasey, Professor, Liverpool School of Tropical Medicine, United Kingdom; Professor Pan Zhao, Chief Physician, Fifth Medical Center (formerly Beijing 302 Hospital) Chinese PLA General Hospital, China; Professor Puneet Dhar, Professor and Head Surgical Gastroenterology, Risikesh All India Institute of Medical Sciences , India; Professor Rita Olans, Assistant Professor, MGH Institute of Health Professions, United States of America; Professor Sue Burton, Assistant Professor Pharmacy Practice, Rhodes University, South Africa; Professor Surya Prakasa Rao, Dean, Narayana Medical College, India; Professor Syed Tabish Tazi Zaidi, Associate Professor, University of Leeds, United Kingdom; Rafael Beger, Clinician, Hospital Regional do Vale do Paraíba São Paulo , Brazil; Stephen Hughes, Antimicrobial Consultant Pharmacist, Chelsea & Westminster NHS Trust, United Kingdom; Zhou Mi, Clinical Pharmacist, Soochow University, China

5 Treasurer's Report

To approve:

The audited accounts for the period 1 October 2019 – 30 September 2020

The appointment of MacIntyre Hudson as accountants and auditors for the period 1 October 2021-30 September 2022.

6 To receive the Trustees report (including reports on meetings, education, journals & grants)

7 Date, time, and place of the next meeting: to be notified

8 Investiture of President

9 Any other business

Unconfirmed minutes of the meeting of the Annual General Meeting held 28 May 2020

1 Welcome and apologies for absence

The President welcomed Members to the Annual General Meeting, being held virtually due to the COVID-19 pandemic. 42 eligible members were in attendance. Apologies for absence were noted.

2 Minutes of the 2019 Annual General Meeting

The minutes of the 2019 Annual General Meeting held 20 March were **RECEIVED** and **SIGNED** as a true record.

3 President's report

The President reported that the year under report was for the period 1 October 2018 – 30 September 2019 and did not cover any period of the current and ongoing COVID-19 pandemic.

Those present heard that the year had been a busy year that included some landmark achievements for the Society. Most notably the Society launched JAC-Antimicrobial Resistance, a new fully open access online journal; members joined the President in congratulating all involved in its development and launch. During the year the Society has made membership cost free and achieved a healthy increase in applications, especially from lower- and middle-income countries where a paid membership had been a barrier to membership for many.

During the year, the Society decided to down its grants programme for one year to undertake a review of its funding strategy. Council had acted swiftly however in light of the pandemic and next year the assembly will hear of a COVID-19 funding programme established to address the immediate needs of the research community.

The President was delighted to report the launch of the BSAC Infection Learning Hub to house an increasing number of e-learning courses. The Society has developed over 20 e-learning courses to date on a range of topics in the infection management and stewardship arena, all are open access at point of access and have attracted learners from 200+ countries across all continents.

It was noted that the BSAC Resistance Surveillance Programme entered its final year after running for 20 years. Council agreed to establish a successor programme that will focus on real time data collection through a new Drug Resistant Infections Registry that remains under discussion with plans to launch in 2021. The President reported that the Society is working to identify to find a new home for the isolate biobank generated by the Resistance Surveillance programme to extend the impact of this important work over the years to come.

Other areas of success have been political engagement which strengthened during the year, with regular meetings with the Deputy CMO and UK Envoy on AMR. Since the end of the reporting period, we have also met with the incoming Chief Medical Officer, Chris Whitty. The President said there were many more activities such as OPAT and Drug Stability Testing that he could talk about if not constrained by time. He commended members to read Trustee's report or visit the BSAC website for further information.

He ended by thanking all those who have supported BSAC and paid tribute to those who sadly died since the last AGM, including four longstanding members, editors, and officers of BSAC - William Brumfitt, Past President, David Reeves, former Council member and Editor in Chief, Johan Mouton, Editor and Kate Gould – a longstanding member and Officer of BSAC.

4 Elections

Those present noted in accordance with Articles 47 – 63, the elections and re-elections of the following officers to the Society:

- A. The election of David Jenkins to serve as Vice President (President-Elect) 2020-2021, President 2021-2024 and Vice President (Past President) 2024-2025
- B. The re-election of Helena Parsons and Jonathon Sandoe as Ordinary Members of Council to serve a second and final term of office 2020-2023

And in accordance with article 7 those elected to Ordinary Membership of the Society.

5 Financial Report

The Honorary Treasurer presented the audited accounts for the period 1 October 2018 – 30 September 2019, reminding the assembly that the financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

It has been another positive financial period for society finances. During the period the overall worth of the Society grew by £611,805 (7.9%) to £8.4 million. This growth was due to recognised net gains on our investment portfolio of £223,000 and an increase in income over expenditure of £390k. In terms of income there has been a decrease in dependence on Journal income from 60% to 55%, a trend we will seek to continue over the forthcoming year, although the impact of COVID-19 on our activities and associated income is to be seen.

The assembly noted that as in previous years Council has operated an annual budgeting and planning process and principal sources of funding were income from the Journal of Antimicrobial Chemotherapy, revenue from meetings activities in the form of delegate registration fees, sponsorship, and unrestricted educational grants from Industry.

It was noted that Council has agreed that BSAC will, as is expected by the Charity Commission, use some of its investments to underwrite or continue to underwrite three activities. Over the next 3 years we will, if required, draw funds from investment to complete the commitment of £300,000 made to the Drug Stability Programme invest in a full capital refurbishment and remedial works programme to a total of £600,000 of the BSAC headquarters, which the Society has owned for a decade but not invested in to date.

In closing the Honorary Treasurer thanked those companies and organisations who generously provided unrestricted educational grants, gifts in kind and sponsorship that enabled the Society to deliver educational benefits to its Membership and the wider antimicrobial community during the past year.

In speaking of the future, the Treasurer reported that the advent of COVID-19 has changed our operations, as it has for many organisations. We are working behind the scenes to reshape BSAC and its finances to ensure the impact is minimal, although there may be significant differences to report in 2021. The Society is reshaping its events offerings and hoping to secure some income to support this but does accept there will be a drop in income here for the current financial year.

Lastly the reported that the Society has undertaken a post year end evaluation via the auditors and will be adjusting the Trustees report to state that financial statements have been prepared on a going concern basis. The Trustees have considered relevant information, including the post year end performance and the impact of subsequent events in making their assessment. The COVID-19 pandemic and the ensuing economic shutdown has had a minimal impact on the company's operations. Based on these assessments and having regard to the resources available to the entity, the Trustees have concluded that there is no material uncertainty and that they can continue to adopt the going concern basis in preparing the annual report and accounts.

In closing the Honorary Treasurer added his thanks to those of the President to those companies and organisations who generously provided unrestricted educational grants, gifts in kind and sponsorship that enabled the Society to deliver educational benefits to its Membership and the wider antimicrobial community during the past year.

The Assembly:

- A **RECEIVED** and **APPROVED** the company accounts for the period 1 September 2018 – 30 September 2019.
- B **NOTED** the appointment of MacIntyre Hudson as the Society's auditors for the period 1 October 2019 – 31 October 2020.

6 Finance report

The Honorary Treasurer presented the audited accounts for the period 1 October 2017 – 30 September 2018, reminding the assembly that the financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

The Treasurer reported on the appointment of new accountants since the last AGM and the accounts are assembled differently to the past year so some of the comparative figures are different.

Those present heard that it has been another largely positive financial period for society finances. During the period the overall worth of the Society grew by £700,000 (10%) to £7.8 million. This growth was due to recognised gains on our investment portfolio and an increase in income over expenditure with the operating balance shows a deficit of income over expenditure of £158k, which is largely due to an anticipated fall in designated income for surveillance activities. There are no real surprises in the accounts with income and expenditure as planned for. Taken over 2 years the Society is running at a surplus of income over expenditure of £112k. Overall the Society expended 67% of its income on charitable activities and 2% on governance (Council expenses) with the remaining 31% being the cost of generating charitable income.

The assembly noted that as in previous years Council has operated an annual budgeting and planning process and principal sources of funding were income from the Journal of Antimicrobial Chemotherapy, revenue from meetings activities in the form of delegate registration fees, sponsorship and unrestricted educational grants from Industry. Journal income for the period was £1.3 million (2016/17 - £1.35 million) and following deduction of publisher's expenses of £294k (2016/17 £296k), provided income totaling £1 million before deduction of internal costs. The Treasurer was pleased to report that this was above the guaranteed income threshold contracted for with our publishers Oxford University Press.

It was noted that Council has agreed that BSAC will, as is expected by the Charity Commission, use some of its investments to underwrite three activities. Over the next 3 years we will, if required, draw funds from investment to underwrite the Drug Stability Programme (to a maximum of £300,000), development of a new open access journal platform (to a maximum of £300,000) and invest in a capital refurbishment and remedial works programme of the BSAC headquarters, which the Society has owned for a decade but not invested in to date.

In closing the Honorary Treasurer thanked those companies and organisations who generously provided unrestricted educational grants, gifts in kind and sponsorship that enabled the Society to deliver educational benefits to its Membership and the wider antimicrobial community during the past year.

6 Reports of the Editors-in-Chief of JAC (Peter Donnelly) and JAC-AMR (Dilip Nathwani)

The Editors in Chief had prepared and circulated written reports on the activities of the Journals that had been circulated ahead of the meeting. Those present were invited to email the office if they had any questions to raise arising from these reports.

7 Trustees report

Members **RECEIVED** the Trustees report published at pages 12-19 of the agenda, noting that the report forms part of BSAC's formal submission to the Charity Commission and Companies House and details all activities for the reporting year in addition to the audited accounts.

8 Date, time and place of the next meeting

To be announced.

9 Any other business

There being no other business the meeting was declared closed.

Reference and administrative details of the company, its trustees and advisers for the year ended 30 September 2020

Trustees

Dr Mark Gilchrist
Dr Paul Frederick Long
(Professor) Frances Kate Gould (resigned 28 April 2020)
Dr Sanjay Patel
Dr Helena Kate Parsons
Dr Jonathan Sandoe
Dr Philip Howard
Dr Michael Charles Allen
Dr Christopher Longshaw
Enas Newire
Dr Oliver Van Hecke
Dr Naomi Fleming
Daniel Hassan
Dr Jessica Blair
Professor Ian Gould
Sally Tipping
Neil Powell
Dr David Richard Jenkins (appointed 28 May 2020)

Company registered number

04443910

Company registered number

1093118

Registered office

Griffin House, 53 Regent Place, Birmingham, B1 3NJ

Chief executive officer

Mrs Tracey Guise

Investment advisors

Rathbones Management Investment Ltd, 159 New Bond Street, London, W1S 2UD

Trustees' Report for the period ended 30 SEPTEMBER 2020

The Trustees present their annual report together with the audited financial statements of the company for the 1 October 2019 to 30 September 2020. The Trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) as amended by Update Bulletin 1 (effective 1 January 2015).

Since the company qualifies as small under section 383, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is not required.

Objectives and Activities

Trustees responsibilities in relation to the financial statements

The Trustees (who are also directors of British Society for Antimicrobial Chemotherapy for the purposes of company law) are responsible for preparing the Report of the Trustees (incorporating a directors' report) and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing these financial statements, the Trustees are required to:

- Select suitable accounting policies and apply them consistently;
- Observe the methods and principles in the Charities SORP;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Statement as to disclosure to our auditors

In so far as the Trustees are aware:

- There is no relevant audit information of which the charitable company's auditor is unaware; and
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislations in other jurisdictions.

Reference and administrative details

The British Society for Antimicrobial Chemotherapy is both a company limited by guarantee (Registered Company 4443910) and a registered charity (Registered Charity 1093118). It was incorporated on 21 May 2002, having operated as an unincorporated charity since being founded in 1971. The principal and registered address of the Charity is Griffin House, 53 Regent Place, Birmingham, B1 3NJ.

The names of the Trustees at the date of approval of the report, and the names of those who served during the financial year are:

1 October 2019 – 30 September 2020

Mr Philip Howard, Consultant Pharmacist, Leeds General Infirmary, Leeds

Mr Mark Gilchrist, Consultant Pharmacist, Imperial College London

Dr Paul Long, Reader in Pharmacology, Kings College London, London

Dr Jonathan Sandoe, Associate Clinical Professor Microbiology, Leeds

Dr Helena Parsons, Consultant Microbiologist, Sheffield

Dr Sanjay Patel, Consultant Infectious Diseases Paediatrician, Southampton General Hospital, Southampton

Enas Newire, PhD Student, London
 Michael Allen, Medical Affairs, Merck Inc
 Oliver Van Hecke, Academic General Practitioner, London
 Dr Jessica Blair, Academic Microbiologist, Birmingham
 Dr Naomi Fleming, Community based Pharmacist, Towcester
 Professor Ian Gould, Consultant Microbiologist, Aberdeen
 Mr Daniel Hansell, PhD Student, Durban, South Africa
 Mr Neil Powell, Consultant Antimicrobial Pharmacist, Cornwall
 Mrs Sally Tipping, Lead Antimicrobial Pharmacist, Swindon

1 October 2019 – 27 March 2020

Professor Frances Kate Gould, Consultant Microbiologist, Freeman Hospital, Newcastle upon Tyne (deceased)

The name of the Society's Chief Executive Officer, the senior staff member to whom the trustees delegate day-to-day management of Society affairs, is Mrs Tracey Guise.

The names and addresses of the Society bankers, accountants, investment advisers and solicitors are recorded below:

Bankers

Lloyds-TSB
 Colmore Row
 Birmingham, B3 3BP

Accountants

MacIntyre Hudson LLP
 Peterbridge House, The Lakes
 Northampton, NN4 7HB

Investment advisers

Rathbones Management Investment Ltd
 159 New Bond Street
 London, W1S 2UD

Solicitors

Hempsons Solicitors
 20 Embankment Place
 London, WC2N 6NN

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The governing document is the Memorandum and Articles of Association (MAA) that is regularly reviewed by Council. The Society Regulations further define the MAA. These documents are published on the Society website.

Election of Trustees

Elected Members of Council act as Trustees and Directors of the Society. The procedure for the election of Trustees is set down in the Articles of Association and further defined by the Regulations. In summary, Council comprises Ordinary Members of Council who are elected by an open process of nomination and, when nominations exceed the number of vacancies, by postal ballot of the Membership; this ballot is conducted by the Electoral Reform Services and Officers of the Society who are elected by Council.

Induction of Trustees

An internal induction programme for Trustees exists. Trustees receive an induction pack that includes information on the statutory responsibilities of Trustees and directors, structure of the Society and timecommitment/duties of a Trustee. At the time of appointment Trustees are required to confirm their eligibility to serve as a Trustee and complete a declaration of interests form for inclusion on the Society Declaration of Interests Register. In addition, the Society offers the opportunity for all newly appointed and existing Trustees to attend training courses on the roles and responsibilities of Trustees. The cost of these courses is met by the Society.

Pay policy for staff

The pay of the senior staff is reviewed annually by Remuneration Committee that comprises senior officers of the society and normally increased in accordance with average earnings. In view of the nature of the charity, the directors benchmark against pay levels in other not for profit organisations and learned societies. The remuneration bench-mark is the mid-point of the range paid for similar roles with a single salary scale allowing for salary adjustments for any additional responsibilities. During the past year the Remuneration Committee received, considered and made their decisions regarding salary supported by the results of a salary survey conducted by the Professional Associations Research Network.

ORGANISATIONAL STRUCTURE AND DECISION MAKING

The Council meets three times annually to consider statutory and financial business and to determine policy for the charity. Standing Committees are overseen by elected Officers and are each responsible for a major area of BSAC activity. Each of the Standing Committees has delegated authority to carry out work agreed by Council and each report its activities back to Council. Details of the overarching structure, composition and remit of each Committee are published on the Society website.

RISK MANAGEMENT

The Trustees acknowledge their responsibility to assess and manage the risks that the Society faces or might face in future. A consolidated risk register, developed using Charity Commission guidance, is maintained by the Society. Officers and senior staff are required to identify and analyse risks relevant to their responsibilities, assess risks according to their likely occurrence and impact and report on procedures that are in place to manage the risks. The risk management process is overseen and reviewed by Council.

To minimise conflicts of interest, the Society maintains a Register of Interests. Those appointed to act on behalf of the Society (Trustees, Chairs of working parties, editors, referees, etc.) are required to complete a declaration of interests' form, which is recorded centrally at BSAC HQ. Details about the risk register are published on the Society website. There was a full review and update of the risk register and transparency declarations in 2014 and both registers are updated on an annual and ongoing / as required basis. A full review of both registers was planned for 2020 but deferred to 2021 due to the impact of COVID19 pandemic on office operations.

REVIEW OF OBJECTIVES, ACTIVITIES, ACHEIVEMENTS AND PERFORMANCE

Objectives

The purpose of the BSAC, as described by the objects of the Society is to “facilitate the acquisition and dissemination of knowledge in the field of antimicrobial chemotherapy.”

Between October and January of each year Council agrees a programme of work and a budget for the forthcoming year. This programme of work includes a range of educational, meetings, grant giving and other activities that are in accordance with, and aimed at furthering, the objects of the Society.

During the year Council referenced, adjusted and worked towards fulfilment of its agreed strategic framework for 2019-2021. The strategic framework includes mission statements, key messages and desired deliverables relevant to the current agreed objectives of the society. The aim of the strategic framework and timetable is to enable all elected officers and Council Members the opportunity to be actively involved in setting the agenda for the future, without having undue influence over it, and regularly measuring progress and outcomes against it. The COVID19 pandemic meant the Society had to swiftly re-evaluate its activities from March 2020 onwards, mitigate risks for planned activities and identify its response and offerings to the healthcare community in light of the pandemic. The Society undertook a full evaluation of the risks posed and impact on income and provided a report to its auditors and, as part of the audit for the period ended 30 September 2019, the auditors were satisfied the Society would continue as a viable ongoing concern.

Public benefit

The Trustees have read the guidance on public benefit provided by the Charity Commission. The Society ensures that its activities are as far as possible to the public benefit by ensuring patient/public involvement and the development of educational initiatives directly aimed at members of the public. During the past year Dr Nicholas Brown served as the BSAC Director for Professional and Public Engagement, serving as a co-opted member of Council and overseeing the work of the All Party Parliamentary Group on Antibiotics and the advocacy work it undertakes to raise the profile of antimicrobial resistance within civil society.

Grants

Trustees and the Grants Committee go to great lengths to obtain due diligence in the refereeing of grant applications and continues to support its policy of only supporting those applications that are of a high standard. To ensure that the grant award process is as transparent as possible, the Society has developed Standard Operational Procedures for Grants that are regularly reviewed and updated. During the year the Society secured grant funding of £105,000 from two commercial companies and alongside funding from BSAC charitable income funded 11 grants focussed on COVID19 research. The Grants Committee met once during the year and awarded the following grants:

- King's College London, London, England, Targeting intracellular vesicular trafficking using a novel V-ATPase inhibitor to ameliorate pathogenicity of SARS-CoV-2 and related viral pathogens, £25,000
- University of Toronto, Canada, Control of COVID-19 outbreaks in long term care, (CONTROL-COVID), £25,000
- King's College London, London, England, Characterising the effects of immune-modulating drugs on the T cell immune response to COVID 19, £24,070
- Imperial College London, London, England, Utilising novel antimicrobial agents to restore dysregulated immunity to SARS-CoV-2 in high risk patients, , £25,000
- King's College London, London, England, A scalable workflow for rapid population-wide diagnostics of COVID-19, £24,969

- University of Strathclyde, Glasgow, Scotland, Accelerated introduction of a novel class of resistance-proof antiviral drugs: Strathclyde Minor Groove Binders, £23,415
- University of Bristol, Bristol, England, Harnessing High Performance Computing Tools in a COVID-19 Drug Repurposing Pipeline, £24,736
- Imperial College/ Imperial Healthcare NHS Trust, London, England, The anti-viral and anti-cytokine effects of baricitinib: stitching together a dual mechanism, £25,000
- Quadram Institute Bioscience, Norwich Research Park, Norwich, England, Intramolecular trans-sialidase as alternative therapeutics against COVID-19, £25,000
- Poseidon LLC, Pasadena, California, Development of a novel small non-antibody protein scaffold as a therapy to reduce the SARS-Cov2 viral load, £25,000
- Yale University and Howard Hughes Medical Institute, New Haven, Connecticut, A humanized mouse model of COVID-19 harnessing the clinical potential of patient-derived antibodies, £25,048.

Further the Society secured a \$1 million donation to be expended on grants programme for research projects in the area of COVID19 and the impact on antimicrobial resistance. The funding was negotiated during the financial year ended 30 September 2020 but was not received until October 2020 and will be expended on two separate funding calls, details of which will be published in the 2020/21 Trustees Report.

Education

During 2019-2020 the Society continued to support the development of clear and well-funded initiatives in education that are designed to support the education and training needs of clinicians, junior doctors, scientists and technicians, in addition to allied health professionals and that are of wider benefit to the public. The Society continued to promote the first global Massive Open Online Course on Antimicrobial Stewardship (MOOC-AS) which was developed in partnership with the University of Dundee and develop a wide portfolio of open access e-learning courses in English and translated languages. The BSAC virtual learning hub was redeveloped and launched as the Infection Learning Hub (www.infectionlearninghub.com) and the courses provided have attracted over 200,000 active learners from 6 continents and 205 countries across the globe.

Workshops

Throughout the period moved planned conferences and meetings to online platforms and delivered a series of webinars and virtual conferences.

Web-based educational resources

During the period the Society maintained the range of educational resources available via its website. These include:

Webcasts and PowerPoint slide sets: This facility increases the number of individuals able to benefit from the Society's educational programmes and provides valuable learning materials for those unable to attend meetings in person.

Education around antimicrobial prescribing remains as one of the key strategies for supporting antimicrobial stewardship activities, and both resources and other e-learning modules aim to educate and empower health care professionals to provide high quality and safe infection prevention and management across healthcare communities that will enhance the health of the populations they serve.

The Society maintained an open access repository of peer review and non-peer review resources to support health care professionals across the globe to support the World Health Organisation global action plan on antimicrobial resistance. In addition the Society developed a COVID-19 Hub through which to share open access research and resources on COVID19.

Susceptibility Testing

The Society continued to support the United Kingdom contribution to the European Antimicrobial Susceptibility Testing methodology – EUCAST and underwrote a service provision contract in this area with Public Health Wales. This activity fulfils the three-main charitable objective headings as the Society educates health professionals in susceptibility testing methodology, communicates outputs to the Membership and wider profession and undertakes research to ensure the European methodology is accurate and continually updated.

Resistance Surveillance

In collaboration with the Public Health England and Industry, the Society continued to support the UK national programmes of antibiotic resistance surveillance (respiratory & bacteraemia). The results of the surveillance programme are freely available to members and the wider community via a web-based database and provide valuable information to those involved in the field. In addition, the Society has amassed a library of over 50,000 isolate strains which are made available at cost price to the international research community. The Society furnished a range of contractual arrangements for the supply of isolates to

academic and commercial contractors, primarily for use in research projects, The Society, having been mindful for several years of the financial vulnerability of the programme, looked at the future of the programme during the year and is developing an options appraisal for its continuance or cessation beyond 2020. Council took the decision to end the Resistance Surveillance Programme at the end of October 2020. A process of open competition led to the isolate library of 50,000 strains being awarded to a consortia research group led by Universities of Dundee and Edinburgh. The isolate library will be transferred in early 2021 when all contractual requirements of the programme have been fulfilled. The Society will, under contract, continue to benefit from any commercialisation of research arising from use of the isolates over a period of 5 years.

Outpatient Parenteral Antimicrobial Therapy (OPAT)

The Society published on a dedicated website the outputs of its Outpatient Parenteral Antimicrobial Therapy (OPAT) project, which supports establishing treatment services for serious infections in the home environment. The Society continued to support, through meetings and provision of free at point of use resources, the development and implementation of services within the UK. The programme continued to support the Drug Stability initiative during the year to provide open access data on the stability of medicines in elastomeric devices, data currently not openly available to the field. Details of all work in progress can be reviewed at www.e-opat.com.

Meetings

The Society hosted and/or participated in many national and international meetings during 2019-20 until the first restrictions due to COVID-19 were implemented. Meetings included:

The 17th Antibiotic Resistance and Mechanisms Workshop held in November 2019. This remains a premier event in the society's calendar and offers members of the UK community researching mechanisms of antimicrobial resistance the opportunity to meet to consolidate and extend the expertise held within individual laboratories in the United Kingdom. As in previous years, the workshop provided a much-needed forum to allow the sharing of knowledge between all grades of researchers, including PhD students and technicians. The Society continued to underwrite the cost of PhD students, early career researchers and trainees.

The Society participated in International Conferences on Antimicrobial Stewardship in Africa and established a Middle East North Africa collaborative, meeting in Dubai in February 2020. These international activities enable the Society to support sharing and advancement of knowledge and skills for running successful hospital-based stewardship programs.

The traditional March Spring Conference was cancelled and the Annual General Meeting was held remotely with permission of the Charity Commission in May 2020.

All Society organized meetings, e-learning courses and webinars are accredited for Continuing Professional Development under the statutory scheme operated by the Royal College of Pathologists, and when appropriate, the Royal College of Physicians of London. The Society is required, as part of this process, to issue evaluation questionnaires for each event. The responses provided by these anonymous returns allow the Society to monitor the effectiveness of its activities in this area and enables measures for improvement to be introduced.

Guideline Development Groups

The Society supports several guideline development groups that are charged with producing evidence-based guidance within the field of antimicrobial chemotherapy. Details of guideline development groups are published on the Society website, as are details of the publications produced by them. These publications are subject to a process of national consultation and are primarily published in peer-review journals, thus assisting to ensure that working party outputs are scientifically / academically credible and reach the audiences for whom they are intended. It was agreed during the year that the future focus would be on promoting the evidence based guidance produced by others internationally, with the Society investing and focussing on the development of Good Practice Recommendations where required, these being highly used and less labour and cost intensive to produce.

BSAC International

Despite its "British" title the Society has an international membership, and its peer review journal is internationally recognised and renowned. This is also reflected in the activities undertaken by the Society, many of which influence not only UK practice but also contribute to the shaping of international practice, opinion and research. The Society continued to regularly liaise with peer organisations across the globe and, as in recent years, strengthened its alliances through the OPAT, Antibiotic Action and Quality Improvement initiatives amongst others and now its global Massive Open Online Course on Antimicrobial Stewardship.

During the period, the Society hosted sessions and/or supported speakers at many international meetings and developed collaborative relationships with several external groups. Full details of collaborative relationships are published on the BSAC website.

Public facing activities

Council continued to fulfil its aim of improving public education about infection prevention and appropriate use of antibiotics through a range of activities. Of most note was development of a new public facing initiative Stop Superbugs, developed during the year and due for official launch in October 2020.

During the period the Society continue to advocate the use of the e-Bug educational website that contributes to national and Europe-wide curricula for primary school children. In addition, the Society funded the development of Mould the Musical, both school and professional versions. School versions premiered in Scotland and London and the professional version enjoyed an award-winning sell-out run at the Edinburgh Fringe. Plans to roll the school play out to 50+ schools in Cornwall are ongoing, if somewhat delayed due to the impact of the COVID19 pandemic.

The Society continued to serve as secretariat to the All-Party Parliamentary Group on Antibiotics and the group continues to ensure that the topics of antibiotic discovery, development, and resistance receive the political interest required to ensure current and future action.

Communication

The Society continues to communicate with its membership via many different media, including the journal, email, website, e-newsletters and scientific meetings. The Society's websites remain one of the primary routes through which BSAC communicates with the membership and wider community. The sites are open to Members and non-Members alike and provide visitors with easy access to resources on antimicrobial chemotherapy and its allied fields. BSAC continues to recognise the important of, and extend its reach via, social media outlets such as Twitter and Facebook and used viral networking opportunities to deliver messages about appropriate use of antibiotics to public audiences.

Working with others

The Society's relationships with its sister organisations, industry and government are key in ensuring the successful delivery the Society's agenda. The Society continued to work with many organisations that operate under the umbrella of the Federation of Infection Societies, sharing agenda and meetings wherever possible to streamline activities and reduce costs of delivering increased benefits to greater numbers of people. The Society is also a partner in the Learned Societies Partnership LeSPAR.

During this period the Society worked with a range of external organisations, including peer group societies, governmental agencies, pharmaceutical companies and allied health groups within the UK, Europe and rest of the world. The Society continued to develop its relationships with pharmacists, infection control specialists and surgeons, all of whom now are actively involved in the development of meetings and educational events and closer collaboration with nursing colleagues in fulfilment of its stated aims. Through the inclusion of all relevant stakeholders in its activities BSAC continues to ensure that there is a unified voice on infection prevention, detection and management in the UK.

The Society is mindful of the need to engage meaningfully with patients to take on board their views and meet their needs and does so through representation on Council, guideline development groups and patient presentations at conferences as and when appropriate.

JAC-Antimicrobial Resistance

The Society's fully open access journal launched in 2019 - JAC-Antimicrobial Resistance (JAC-AMR) continued to develop during the year. The education component of JAC-AMR is an innovative online repository for educational resources intended to support learning and increase knowledge about antimicrobial stewardship practice, antimicrobial resistance, behaviour change and more, for a worldwide audience. The research component will publish clinically oriented opinions, reviews and original articles that advance the science and knowledge of antimicrobial resistance, stewardship and use relating to antibacterial, antifungal, antiviral and antiprotozoal agents. The Journal publishes primarily in human medicine, but articles in veterinary medicine will be considered, provided they fall within the scope of a regional or global 'one health' approach to antimicrobials.

Journal of Antimicrobial Chemotherapy

The Journal continues to be recognized as a leader in its field and is one of the major routes by which the Society fulfils its educational objectives to disseminate information about antimicrobial chemotherapy. The Journal has continued its policy of publishing BSAC Guideline Development Group reports and systematic reviews of topics in the area of antimicrobial therapy, with a view to promoting the practice of evidence-based medicine. The Journal content becomes freely available on-line 12 months after publication, thus benefiting the profession and consumers alike. During the year the Society worked on development of a second Journal title – JAC-Antimicrobial Resistance, which will be a fully open access research journal and educational platform. Innovative in approach and design the platform will be launched during the next year and will provide a second peer review platform for extending reach and benefits to the healthcare professional community and scientists.

Other significant matters

The Society remained in negotiation with an academic institution regarding commercialisation of Intellectual Property arising from research work funded by a grant provided by the Society. Discussions remain ongoing; with a provisional agreement reached on a percentage income share for the Society should commercialisation proceed. The over-riding principle during discussions was to not commit the Society to additional financial outlay or risk whilst ensuring a fair and appropriate return is possible, as outlined in the terms and conditions for the award of peer review grant funding. Discussions did not conclude during the past year and remain ongoing. The Society continued to work towards diversification of income streams during this period, to reduce risk of reliance on income from the journal and continued to review its supplier base to ensure best value for money and ensure spread of risk.

The Council of the Society approved a full refurbishment of its HQ building at 53 Regent Place to provide a business headquarters that better reflects the tone, tenor and operation of the Society, provide improved flexible and IT enabled meetings spaces and working environment for staff and visitors. Once refurbished the building will also provide disabled access and disabled accessible facilities. Work commenced in July 2020 and completion is anticipated by November 2020.

Financial review

The audited accounts for the period 1 October 2019 – 30 September 2020 are included in this report. The Society remains financially sound and to maintain this position, Trustees continued to review the Society's financial planning and budgeting procedures, as defined in the financial standing orders. Especial consideration will be given to the impact of COVID19 on income opportunities and required expenditure. The Society is within the infection arena and as such there is a demand for the services it provides which, within a difficulty financial climate for some, provides reassurance for the financial viability of the Society. The Society adheres to the principles for expenditure and expense claim guidance that is published on the BSAC website. In 2018-19 the Society continued to operate an annual budgeting and planning process, which was overseen and approved by Council, and as of this period built according to the new governance structure.

During the period the principal sources of funding were income from the Journal of Antimicrobial Chemotherapy, Membership Subscriptions and revenue from meetings activities in the form of delegate registration fees and unrestricted educational grants from Industry. Income from the external publishers of the Journal of Antimicrobial Chemotherapy was £1,284,431 less external publisher's expenses £257,427 realising net income of £1,027,004 before additional in-house editorial costs.

The Society is very grateful to several pharmaceutical companies that generously provided unrestricted educational grants that enabled the Society to deliver educational benefits through meetings to delegates at greatly reduced, or complimentary, rates.

As planned, Council spent £240,612 from the designated funds, the majority of which was expended on the Society's public engagement programme. The general fund is largely represented by the investment portfolio, which performed well in a difficult market with realised and unrealised gains of £27,689. The Society developed revised contractual arrangements for the supply of isolates to academic and commercial contractors, primarily for use in research projects. The Trustees intend to retain the investment portfolio to generate income that will support the long-term fulfilment of the Society's charitable objectives.

To ensure compliance with the law as established by the Bribery Act 2010, Council has developed and approved an Anti-Bribery Policy Statement, a copy of which is published on the Society website.

Council remains mindful of the need to ensure funds are dispersed in furtherance of its aims through a range of charitable activities. The Society now has designated funds for future allocation of funds to grant, education and meeting activities. Further, the Society has a restricted fund through which it supports the national programme of resistance surveillance. Council has charged itself with continuing to examine the range of general, designated and restricted funds it holds to ensure that monies are transferred and dispersed on grants, resistance surveillance, and education and meetings activities in an appropriate and timely fashion.

Investments

The Society investment portfolio is managed by Rathbones Management Investments Ltd, with whom Officers of the Society meet on an annual basis to review and discuss future policy for Society investments. Target income from investments is set at £100,000pa.

The charity's investments are managed according to the powers defined by the Memorandum and Articles of Association. A balanced investment portfolio is maintained, and the investment advisers have been charged with increasing income from investments whilst protecting the capital value of the fund, this being the policy position of Council. The Society has placed certain restrictions on the way in which the fund is managed, including precluding investments in named pharmaceutical companies to ensure conflicts of interest, perceived or real, do not arise.

Reserves

The Trustees' policy is to maintain a level of free reserves equivalent to not less than 24 months expenditure and aim to have a reserve for 36 months expenditure. This policy would enable the Society to remain operational for between 24-36 months (estimated at £4 million against total free reserves of £6,141,111 and fulfil its commitments in terms of grants, education and meetings activities, some of which are subject to a 3-year planning / completion cycle.

The future

The Trustees remain confident that the Society is, through the activities described in this report, meeting and furthering the aims and objectives of the Society. Through careful planning and collaboration with the Membership and relevant external organisations, Trustees will continue to deliver and develop these activities. The Trustees have a reasonable expectation that the charity will continue in operational existence for the foreseeable future and have, therefore, used the going concern basis in preparing the financial statements.

Post balance sheet events

The Society has considered the operational and financial impact of COVID-19 on future financial performance and prospects of the business. The Trustees have considered the impact of COVID-19 on the range of activities it undertakes and has decided to treat the impact as a non-adjusting event. As declared in the 2017-19 Trustees report, COVID-19 has presented both risks and opportunities to the Society; the meeting and events activities have been reshaped and will be delivered as online virtual events and e-learning activities which in the fulness of time will return benefits to the Society similar to in-person events. One impact of COVID19 has been a reduced requirement for administrative support leading to one redundancy. A second redundancy due to closure of projects and activities has led to a reduction in salary and pension costs going forward. The Society secured additional income of over £1 million to support a COVID-19 Grants funding programme. Whilst these restricted funds will not generate a surplus of charitable income they will ensure the Society can continue to meet, and even extend, its charitable activities in the coming year(s). In conclusion the Trustees consider that the Society as an entity remains a going concern.

TRUSTEES' RESPONSIBILITIES STATEMENT

The Trustees (who are also directors of British Society for Antimicrobial Chemotherapy for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

DISCLOSURE OF INFORMATION TO AUDITOR

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

- so far as that Trustee is aware, there is no relevant audit information of which the charitable company's auditor is unaware, and
- that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable company's auditor is aware of that information.

This report was approved by the Trustees, on and signed on their behalf by:

Dr Christopher Longshaw

Trustee

Independent Auditors' report to the members of British Society for Antimicrobial Chemotherapy

OPINION

We have audited the financial statements of British Society for Antimicrobial Chemotherapy (the 'charitable company') for the year ended 30 September 2020 set out on pages 18 to 36. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice). In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 30 September 2020 and of its incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the Trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charitable company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

OTHER INFORMATION

The Trustees are responsible for the other information. The other information comprises the information included in the Annual report, other than the financial statements and our Auditor's report thereon. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Trustees' report is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditor's report.

USE OF OUR REPORT

This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its trustees, as a body, for our audit work, for this report, or for the opinions we have formed.

Elaine Olson-Williams FCCA**MHA MacIntyre Hudson**

Chartered Accountants
Statutory Auditors

Peterbridge House
The Lakes
Northampton
NN4 7HB

Date:

MHA MacIntyre Hudson is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

Statement of financial activities (incorporating an income and expenditure account) for year ended 30 September 2020

	Note	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
INCOME FROM:					
Donations and legacies	2	962,661	59,513	1,022,174	240,870
Charitable activities	3	1,680,640	159,840	1,840,480	2,482,905
TOTAL INCOME		2,643,301	219,353	2,862,654	2,723,775
EXPENDITURE ON:					
Raising funds		25,327	-	25,327	25,391
Charitable activities		2,416,996	240,612	2,657,608	2,309,299
TOTAL EXPENDITURE	6	2,442,323	240,612	2,682,935	2,334,690
NET INCOME / (EXPENDITURE) BEFORE INVESTMENT GAINS		200,978	(21,259)	179,719	389,085
Net gains on investments		57,312	-	57,312	222,720
NET INCOME / (EXPENDITURE) BEFORE RECOGNISED GAINS AND LOSSES		258,290	(21,259)	237,031	611,805
NET MOVEMENT IN FUNDS		258,290	(21,259)	237,031	611,805
RECONCILIATION OF FUNDS:					
Total funds brought forward		8,015,311	358,013	8,373,324	7,761,519
TOTAL FUNDS CARRIED FORWARD		8,273,601	336,754	8,610,355	8,373,324

The notes on pages 22 to 37 form part of these financial statements.

Balance sheet as at 30 September 2020

	Note	£	2020 £	£	2019 £
FIXED ASSETS					
Tangible assets	9	737,517		651,128	
Investment property	10	550,000		465,000	
Total tangible assets			1,287,517		1,116,128
Investments	11		5,313,623		5,503,921
			<u>6,601,140</u>		<u>6,620,049</u>
CURRENT ASSETS					
Debtors	12	447,122		541,652	
Cash at bank and in hand		2,219,517		1,744,023	
		<u>2,666,639</u>		<u>2,285,675</u>	
CREDITORS:					
amounts falling due within one year	13	(657,424)		(532,400)	
NET CURRENT ASSETS			<u>2,009,215</u>		<u>1,753,275</u>
NET ASSETS			<u>8,610,355</u>		<u>8,373,324</u>
CHARITY FUNDS					
Restricted funds	14		336,754		358,013
Unrestricted funds	14		8,273,601		8,015,311
TOTAL FUNDS			<u>8,610,355</u>		<u>8,373,324</u>

The company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The Trustees consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ("the Act") and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act. However, an audit is required in accordance with section 144 of the Charities Act 2011.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

The financial statements were approved and authorised for issue by the Trustees on 21 March 2019 and signed on their behalf, by:

Dr Christopher Longshaw

Trustee

The notes on pages 22 to 37 form part of these financial statements.

Statement of cash flows for the year ended 30 September 2020

	Note	2020 £	2019 £
CASH FLOWS FROM OPERATING ACTIVITIES			
Net cash used in operating activities	16	248,936	(71,841)
CASH FLOWS FROM INVESTING ACTIVITIES			
Dividends, interest and rents from investments		108,290	121,810
Purchase of tangible fixed assets		(101,405)	-
Proceeds from sale of investments		1,031,469	806,569
Purchase of investments		(811,795)	(899,888)
NET CASH PROVIDED BY INVESTING ACTIVITIES		226,559	28,491
CHANGE IN CASH AND CASH EQUIVALENTS IN THE YEAR			
Cash and cash equivalents brought forward		1,744,02	1,787,373
CASH AND CASH EQUIVALENTS CARRIED FORWARD	17	2,219,518	1,744,023

The notes on pages 22 to 37 form part of these financial statements.

Notes to the financial statements for the year ended 30 September 2020

1. ACCOUNTING POLICIES

1.1 General information

The British Society for Antimicrobial Chemotherapy is a private limited company limited by guarantee and domiciled in England and Wales. Registered company number 04443910 and charity number 1093118.

The registered office is Griffin House, 53 Regent Place, Birmingham, B1 3NJ.

1.2 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

British Society for Antimicrobial Chemotherapy meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

1.3 Company status

The company is a company limited by guarantee. The members of the company are the Trustees named on page 1. In the event of the company being wound up, the liability in respect of the guarantee is limited to £1 per member of the company.

1.4 Going concern

The financial statements have been prepared on a going concern basis. The Trustees have considered relevant information, including the post year end performance and the impact of subsequent events in making their assessment. The COVID-19 pandemic and the ensuing economic shutdown has had a minimal impact on the society's operations, as discussed further in the Trustee's report. Based on these assessments and having regard to the resources available to the entity, the Trustees have concluded that there is no material uncertainty and that they can continue to adopt the going concern basis in preparing the annual report and accounts.

1.5 Income

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donated services

No value has been attributed as amounts involved, where an objective value can be determined, are not material.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the Balance Sheet date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All differences are taken to the Statement of Financial Activities.

Quoted investments and investment property

Quoted investments are stated at market value at the period end. Gains and losses on disposal and revaluation of investments are charged or credited to the SOFA. Investment properties are revalued annually and the aggregate surplus or deficit is transferred to the revaluation reserve, therefore no depreciation is provided in respect of investment properties. The Trustees consider that, because these properties are not held for consumption but for their investment potential, to depreciate them would not give a true and fair view.

1.6 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities and Governance costs are costs incurred on the company's operations, including support costs and costs relating to the governance of the company apportioned to charitable activities.

1.7 Tangible fixed assets and depreciation

All assets costing more than £1,000 are capitalised.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Freehold property (exc. land)	-	2% straight line
Computer and other equipment	-	25% straight line

1.8 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless fair value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and shown in the heading 'Gains/(losses) on investments' in the Statement of financial activities incorporating income and expenditure account.

1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at Bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

1.13 Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.14 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

2. INCOME FROM DONATIONS AND LEGACIES

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
Voluntary income: subscriptions	11,769	-	11,769	13,337
Investment income	108,290	-	108,290	121,810
Rental income	26,713	-	26,713	27,146
Sundry income	27,671	43,245	70,916	78,577
Donations re Covid-19	788,218	16,268	804,486	-
	<u>962,661</u>	<u>59,513</u>	<u>1,022,174</u>	<u>240,870</u>
Total donations and legacies				
Total 2019	<u>240,870</u>	<u>-</u>	<u>240,870</u>	

3. INCOME FROM CHARITABLE ACTIVITIES

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
Education	236,030	(1,018)	235,012	509,870
Communications	1,444,610	64,343	1,508,953	1,691,195
Research	-	96,515	96,515	281,840
	<u>1,680,640</u>	<u>159,840</u>	<u>1,840,480</u>	<u>2,482,905</u>
Total 2019	<u>1,994,906</u>	<u>487,999</u>	<u>2,482,905</u>	

EDUCATION

	2020 £	2019 £
MOOC-AS including translations	62,070	5,918
Drive AB	(1,018)	18,266
OPAT	57,412	60,202
Spring Meeting	37,900	78,957
Residential Workshops	9,628	24,283
Susceptibility User Group Days	2,040	7,920
Antibiotic Action	145	5,696
Antibiotic Residence Mechanisms Workshop	15,650	7,389
Other meetings/workshops	49,514	963
Regional Educational Workshops	-	32,805
V Learning	-	617
Stewardship and Surveillance	1,671	248,354
Drug Stability	-	18,500
	<u>235,012</u>	<u>509,870</u>
Total		

COMMUNICATION

	2020	2019
	£	£
Income arising from the society journal and supplements	1,260,567	1,503,302
Resistance surveillance income (40% of total)	64,343	187,893
	<u> </u>	<u> </u>
Total	<u>1,324,910</u>	<u>1,691,195</u>

RESEARCH

	2020	2019
	£	£
Resistance surveillance income (60% of total)	96,515	281,840
	<u> </u>	<u> </u>

4. DIRECT COSTS

	Education	Communications	Research	Total	Total
	£	£	£	2020	2019
	£	£	£	£	£
Meetings	326,373	-	-	326,373	212,080
Sensitivity testing	-	-	38,894	38,894	69,865
Resistance surveillance	-	-	240,612	240,612	395,629
Journal - editorial fees	-	107,313	-	107,313	107,025
Journal - editorial board	-	3,546	-	3,546	21,370
Journal - direct publishing	-	475,470	-	475,470	303,962
Research grants	-	-	272,239	272,239	86,513
Working parties	-	-	1,102	1,102	3,096
Stewardship surveillance	33,153	-	-	33,153	34,420
FCO / MOOC projects	52,542	-	-	52,542	8,488
Staff training	2,345	-	-	2,345	2,735
Miscellaneous	-	4,263	-	4,263	(390)
Grants committee	100	-	99	199	1,153
Other indirect costs	44,705	44,703	44,703	134,111	160,548
Wages and salaries	181,396	181,396	181,396	544,188	469,817
National insurance	19,616	19,616	19,616	58,848	51,173
Pension costs	59,739	59,738	59,738	179,215	157,205
E Learning	95,139	-	-	95,139	24,099
NORS	1,000	-	-	1,000	4,675
Antibiotic DB	171	-	-	171	190
Drug Stability	50,916	-	-	50,916	106,000
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
	867,195	896,045	858,399	2,621,639	2,219,653
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Total 2019	<u>670,484</u>	<u>713,768</u>	<u>835,401</u>	<u>2,219,653</u>	

Other indirect allocated costs

Other indirect allocated costs principally comprise of professional fees, computer costs, premises and accommodation costs of the Society's Headquarters.

Wages, national insurance and pension costs

It has been decided, following an increase in core staff, that staffing costs will from 2017-18 onwards be split equally across the three charitable objective headings of research, communication and education.

Stewardship surveillance

This figure includes expenditure on Drug Stability Programme; OPAT Conference 2018; PPS and OPAT software development, AMR events and workshops.

EDUCATION - MEETINGS

	2020	2019
	£	£
Educational workshops	27,359	26,492
Spring meeting	78,660	74,652
Antibiotic resistance and mechanisms workshop	24,640	24,520
FIS	5,388	6,604
ECCMID	57,191	41,348
Conference	14,602	14,330
OPAT Conference	50,633	24,134
GCCMID	15,715	-
MENA Dubai	44,285	-
Respiratory meeting	7,800	-
Pneumonia	100	-
	<u> </u>	<u> </u>
Total	<u>326,373</u>	<u>212,080</u>

RESEARCH GRANTS

	2020	2019
	£	£
Travel grants	-	420
Phd Studentships	-	48,526
Project grants	-	(11,108)
Research grants	-	42,815
Overseas scholarship	-	5,860
Covid-19	272,239	-
	<u> </u>	<u> </u>
Total	<u>272,239</u>	<u>86,513</u>

5. GOVERNANCE COSTS

	Unrestricted	Restricted	Total	Total
	funds	funds	funds	funds
	2020	2020	2020	2019
	£	£	£	£
Auditors' remuneration	8,435	-	8,435	8,190
Auditors' non audit costs	17,042	-	17,042	13,724
Travel	10,492	-	10,492	67,732
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Total	<u>35,969</u>	<u>-</u>	<u>35,969</u>	<u>89,646</u>

6. ANALYSIS OF EXPENDITURE BY EXPENDITURE TYPE

	Other costs 2019 £	Total 2019 £	Total 2018 £
Expenditure on investment management	25,327	25,327	25,391
Costs of raising funds	25,327	25,327	25,391
Education	867,195	867,195	670,484
Communications	896,045	896,045	713,768
Research	858,399	858,399	835,401
Charitable activities	2,621,639	2,621,639	2,219,653
Expenditure on governance	35,969	35,969	89,646
	2,682,935	2,682,935	2,334,690
Total 2019	2,334,690	2,334,690	

7. NET INCOME/(EXPENDITURE)

This is stated after charging:

	Total 2020 £	Total 2019 £
Depreciation of tangible fixed assets: - owned by the charity	15,016	32,515
Auditor's remuneration - audit	8,435	8,190
Auditor's remuneration - other services	17,042	13,724

During the year, no Trustees received any remuneration (2019 - £NIL).

During the year, no Trustees received any benefits in kind (2019 - £NIL).

8. STAFF COSTS

The average number of persons employed by the company during the year was as follows:

	2020 No.	2019 No.
Employees	12	12

The number of higher paid employees was:

	2020 No.	2019 No.
In the band £60,001 - £70,000	2	1

The above employee is considered to be a key management personnel.

The charitable company was charged £37,425 (2019 - £34,200) by the Public Health Wales for the provision of services to support the activities of the sensitivity testing program.

Total staff costs for the year amounted to £782,251 (2019 - £678,195) including Employers National Insurance of £58,848 (2019 - £51,173) and Employers pension contributions of £179,215 (2019 - £157,205).

9. TANGIBLE FIXED ASSETS

	Freehold property £	Computer and other equipment £	Total £
Cost			
At 1 October 2019	822,438	191,334	1,013,772
Additions	101,405	-	101,405
At 30 September 2020	<u>923,843</u>	<u>191,334</u>	<u>1,115,177</u>
Depreciation			
At 1 October 2019	171,310	191,334	362,644
Charge for the year	15,016	-	15,016
At 30 September 2020	<u>186,326</u>	<u>191,334</u>	<u>377,660</u>
Net book value			
At 30 September 2020	<u>737,517</u>	-	<u>737,517</u>
At 30 September 2019	<u>651,128</u>	-	<u>651,128</u>

10. INVESTMENT PROPERTY

	Long term leasehold investment property £
Valuation	
At 1 October 2019	465,000
Surplus/(deficit) on revaluation	85,000
At 30 September 2020	<u>550,000</u>

The property has been revalued to show the fair value as at 30 September 2020. The revaluation reflects market movements since the last valuation performed in 2017 and takes into account expected rental yields.

11. FIXED ASSET INVESTMENTS

	Listed securities £
Market value	
At 1 October 2019	5,503,921
Additions	811,795
Disposals	(1,031,469)
Revaluations	29,376
At 30 September 2020	<u>5,503,921</u>

Quoted investments

	Cost £	2020 Market value £	Cost £	2019 Market value £
Fixed interest securities UK	904,274	964,061	944,347	1,034,742
Equities UK	1,277,540	1,676,509	1,221,076	1,775,392
Equities overseas	1,167,713	2,001,700	1,252,719	2,049,395
Alternatives	552,989	671,353	613,199	644,392
Total	<u>3,902,516</u>	<u>5,313,623</u>	<u>4,031,341</u>	<u>5,503,921</u>

12. DEBTORS

	2020 £	2019 £
Trade debtors	256,691	368,186
Other debtors	4,847	100,101
Prepayments and accrued income	185,584	73,365
	<u>447,122</u>	<u>541,652</u>

13. CREDITORS: Amounts falling due within one year

	2020 £	2019 £
Other taxation and social security	12,538	13,567
Other creditors	82,193	83,973
Accruals and deferred income	219,323	242,126
Grants	343,370	192,734
	<u>657,424</u>	<u>532,400</u>

Deferred income

	£
Deferred income at 1 October 2019	114,112
Resources deferred during the year	72,070
Amounts released from previous years	(114,112)
Deferred income at 30 September 2020	<u>72,070</u>

Deferred income comprises rental income and project income received in advance.

14. STATEMENT OF FUNDS**STATEMENT OF FUNDS - CURRENT YEAR**

	Balance at 1 October 2019 £	Income £	Expenditure £	Gains/ (Losses) £	Balance at 30 September 2020 £
Unrestricted funds					
General Funds - All funds	8,015,311	2,643,301	(2,442,323)	57,312	8,273,601
Restricted funds					
Resistance surveillance	147,322	160,858	(240,612)	-	67,568
Drive AB	210,691	(1,018)	-	-	209,673
Donations re. Covid-19	-	16,268	-	-	16,268
Spanish translation of the EWMA					
Wound Management Course	-	10,245	-	-	10,245
Sponsor of Webinar	-	9,000	-	-	9,000
Educational grant	-	24,000	-	-	24,000
	358,013	219,353	(240,612)	-	336,754
Total of funds	8,373,324	2,862,654	(2,682,935)	57,312	8,610,355

STATEMENT OF FUNDS - PRIOR YEAR

	Balance at 1 October 2018 £	Income £	Expenditure £	Gains/ (Losses) £	Balance at 30 September 2019 £
General Funds - All funds	7,495,876	2,235,776	(1,939,061)	222,720	8,015,311
Restricted funds					
Resistance surveillance	73,218	469,733	(395,629)	-	147,322
Drive AB	192,425	18,266	-	-	210,691
	265,643	487,999	(395,629)	-	358,013

SUMMARY OF FUNDS - CURRENT YEAR

	Balance at 1 October 2019 £	Income £	Expenditure £	Gains/ (Losses) £	Balance at 30 September 2020 £
General Funds	8,015,311	2,643,301	(2,442,323)	57,312	8,273,601
Restricted Funds	358,013	219,353	(240,612)	-	336,754
	8,373,324	2,862,654	(2,682,935)	57,312	8,610,355

SUMMARY OF FUNDS - PRIOR YEAR

	Balance at 1 October 2018 £	Income £	Expenditure £	Gains/ (Losses) £	Balance at 30 September 2019 £
General Funds	7,495,876	2,235,776	(1,939,061)	222,720	8,015,311
Restricted Funds	265,643	487,999	(395,629)	-	358,013
	<u>7,761,519</u>	<u>2,723,775</u>	<u>(2,334,690)</u>	<u>222,720</u>	<u>8,373,324</u>

15. ANALYSIS OF NET ASSETS BETWEEN FUNDS**ANALYSIS OF NET ASSETS BETWEEN FUNDS - CURRENT YEAR**

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Tangible fixed assets	737,517	-	737,517
Fixed asset investments	5,313,623	-	5,313,623
Investment property	550,000	-	550,000
Current assets	2,329,885	336,754	2,666,639
Creditors due within one year	(657,424)	-	(657,424)
	<u>8,273,601</u>	<u>336,754</u>	<u>8,610,355</u>

ANALYSIS OF NET ASSETS BETWEEN FUNDS - PRIOR YEAR

	Unrestricted funds 2019 £	Restricted funds 2019 £	Total funds 2019 £
Tangible fixed assets	651,128	-	651,128
Fixed asset investments	5,503,921	-	5,503,921
Investment property	465,000	-	465,000
Current assets	1,927,662	358,013	2,285,675
Creditors due within one year	(532,400)	-	(532,400)
	<u>8,015,311</u>	<u>358,013</u>	<u>8,373,324</u>

16. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2020 £	2019 £
Net income for the year (as per Statement of Financial Activities)	237,031	611,805
Adjustment for:		
Depreciation charges	15,016	32,515
Losses on investments	(114,375)	(212,687)
Dividends, interest and rents from investments	(108,290)	(121,810)
Decrease/(increase) in debtors	94,530	(353,217)
Increase/(decrease) in creditors	125,024	(28,447)
	<u>248,936</u>	<u>(71,841)</u>

17. ANALYSIS OF CASH AND CASH EQUIVALENTS

	2020	2019
	£	£
Cash in hand	1,773,723	1,440,693
Money Held by Investment Manager	445,795	303,330
	<u> </u>	<u> </u>
Total	<u>2,219,518</u>	<u>1,744,0233</u>

18. CAPITAL COMMITMENTS

The company had capital commitments for plant and machinery with regards to the refurbishment which was completed on 11 December 2020 of £505,518 (2019 - £nil).

19. PENSION COMMITMENTS

The company operates a defined contribution scheme. The pension cost charge for the year represents contributions payable by the company to the scheme and amounted to £179,055 (2019 - £157,205).

20. ANALYSIS OF CASH AND CASH EQUIVALENTS

At 30 September 2020 the total of the Charity's future minimum lease payments under non-cancellable operating leases was:

	2020	2019
	£	£
Amounts payable:		
Within 1 year	13,981	-
Between 1 and 5 years	52,428	-
	<u> </u>	<u> </u>
Total	<u>66,409</u>	<u>-</u>

21. RELATED PARTY TRANSACTIONS

13 Trustees of the charitable company received £4,658 (2019 - 16 Trustees - £10,223) in relation to reimbursed expenses for travel and subsistence incurred as part of their role as trustees.

Memorandum of Association

- 1 The name of the company (hereinafter called "the Society") is "BRITISH SOCIETY FOR ANTIMICROBIAL CHEMOTHERAPY".
- 2 The registered office of the Society will be situate in England and Wales.
- 3 The objects for which the Society is established ("the Objects") are to facilitate the acquisition and dissemination of knowledge in the field of antimicrobial chemotherapy .
- 4 In furtherance of the Objects, but not otherwise, the Society may exercise the following powers:-
 - 4.1 to institute or assist in instituting, and provide continuing support for, any research in furtherance of the Objects;
 - 4.2 to cause to be written, published, produced and circulated, and to encourage contributions to and publication and production of, periodicals, journals, books, papers, abstracts, pamphlets, posters and other documents and films, videos, recorded tapes and communications in any medium;
 - 4.3 to provide, equip and manage libraries and sources of information in any medium and rooms for the benefit of members of the Society and others;
 - 4.4 to co-operate with persons carrying on research relating to antimicrobial chemotherapy in any part of the world;
 - 4.5 to act as a consultative body on antimicrobial chemotherapy to any Government Department, public or private institution or body of persons on matters pertaining to the Objects;
 - 4.6 to endow Chairs, Readerships, Scholarships, Fellowships and Lectureships at, and provide other support to, appropriate institutions to facilitate the conduct of study and research in furtherance of the Objects;
 - 4.7 to disseminate the useful results of research in furtherance of the Objects;
 - 4.8 to sponsor and hold meetings, symposia, conferences, lectures, classes, seminars, courses and exhibitions either alone or with others;
 - 4.9 to award scholarships, bursaries and prizes in connection with the Society's objects;
 - 4.10 to foster and promote contacts and exchange of information and ideas among persons working in the field of antimicrobial chemotherapy, medical practitioners and other health professionals and the public and to provide a forum to this end;
 - 4.11 to take such steps as may be required for the purpose of procuring contributions to the funds of the Society by way of subscriptions, donations, devises, bequests, grants, subventions or otherwise, provided that in raising funds the Society shall not undertake any taxable trading activities the profits of which are liable to tax;
 - 4.12 to take and accept any gift of money, property or other assets, whether subject to any special trust or not, for any one or more of the objects of the Society;
 - 4.13 to purchase, take on lease or in exchange, hire or otherwise acquire and hold any real or personal property or rights, and to construct, alter, improve, develop, manage and maintain any of the same as are necessary or convenient for the Objects and (subject to such consents as may be required by law) sell, let or otherwise dispose of, turn to account or charge any such real or personal property as may be thought expedient in furtherance of the Objects;
 - 4.14 to apply for, purchase or otherwise acquire and hold or use any patents, copyrights, trade marks, design rights and other intellectual property rights, licences, concessions and the like, conferring any right to use or publish any information, and to use, exercise, develop or grant licences in respect of the property, rights or information so acquired;
 - 4.15 to draw, make, accept, endorse, discount, execute and issue promissory notes, bills, cheques and other instruments and to operate bank or building society accounts in the name of the Society;
 - 4.16 to borrow or raise money for the purposes of the Society on such terms and (subject to such consents as may be required by law) on such security as may be thought fit;
 - 4.17 subject to the provisions of Clause 5 below, to employ such staff (not being members of the Council) as are necessary for the proper pursuit of the Objects and to make all reasonable and necessary provision for the payment of pensions and superannuation to or on behalf of employees, their widows or widowers and other dependants;
 - 4.18 to invest the moneys of the Society not immediately required for the Objects in or on such investments, securities or property and in such manner as may be thought fit and to dispose of or otherwise deal with any investments so made;
 - 4.19 to make any donation either in cash or assets for the furtherance of the Objects;
 - 4.20 to establish and support or aid in the establishment or support of, subscribe to or become a member of any charitable trust, association or institution having charitable purposes in any way connected with all or any of the Objects or calculated to further any of the Objects and to guarantee money for charitable purposes in any way connected with all or any of the Objects or calculated to further all or any of the Objects;
 - 4.21 to undertake and execute any charitable trusts which may lawfully be undertaken by the Society and may promote the Objects;
 - 4.22 to co-operate or associate with other charities, voluntary bodies and statutory authorities operating in furtherance of the Objects or similar charitable purposes and to exchange information and advice with them;
 - 4.23 to acquire and undertake all or any part of the property, assets, liabilities and engagements of any persons, trusts, corporations, associations or other bodies pursuing the Objects;
 - 4.24 to amalgamate with any charity operating in furtherance of the Objects or similar charitable purposes;

- 4.25 to insure and arrange insurance cover for and to indemnify employees, voluntary workers and members from and against all such risks incurred in the course of the performance of their duties in relation to the Society, provided that such persons shall not be indemnified against any wilful or individual fraud and shall be sought to be made liable for such acts;
- 4.26 to establish subsidiary companies;
- 4.27 to pay out of the funds of the Society the costs, charges and expenses of and incidental to the formation and registration of the Society;
- 4.28 to do all such other lawful things as are necessary for the achievement of the Objects or any of them.
- 5 The income and property of the Society shall be applied solely towards the promotion of the Objects and no part shall be paid or transferred, directly or indirectly, by way of dividend, bonus or otherwise by way of profit, to members of the Society and no member of Council shall be appointed to any office of the Society paid by salary or fees or receive any remuneration or other benefit in money or money's worth from the Society provided that nothing in this document shall prevent the payment in good faith by the Society:
- 5.1 of reasonable and proper remuneration to any member, officer or employee for the Society (not being a member of Council) for any services rendered to the Society;
- 5.2 of interest at a reasonable and proper rate on money lent to the Society or of reasonable and proper rent for premises demised or let to the Society by any member or employee of the Society or member of Council;
- 5.3 to any employee or member of Council or of a committee or sub-committee of the Council for reasonable and proper out-of-pocket expenses;
- 5.4 of fees, remuneration or other benefit in money or money's worth to a company of which a member of the Society or of Council may be a member holding not more than one hundredth part of the issued share capital of that company;
- 5.5 of any premium in respect of any indemnity insurance to cover the liability of the members of the Council or of any committee which by virtue of any rule of law would otherwise attach to them in respect of any negligence, default, breach of trust or breach of duty of which they may be guilty in relation to the Society: Provided that any such insurance shall not extend to any claim arising from any act or omission which the members of the Council or of any committee knew to be a breach of trust or breach of duty or which was committed by the members of the Council or of any committee in reckless disregard of whether it was a breach of trust or breach of duty or not and Provided also that any such insurance shall not extend to the costs of an unsuccessful defence to a criminal prosecution brought against the members of Council in their capacity as members of the Council.
- 6 The liability of the members is limited.
- 7 Every member of the Society undertakes to contribute such amount as may be required (not exceeding £1) to the Society's assets if it should be wound up while he is a member or within one year after he ceases to be a member, for payment of the Society's debts and liabilities contracted before he ceases to be a member, and of the costs, charges and expenses of winding up, and for the adjustment of the rights of the contributories among themselves.
- 8 If upon the winding up or dissolution of the Society there remains after satisfaction of its debts and liabilities any property, the same shall not be paid to or distributed among the members of the Society but shall be given or transferred to some other charitable institution or institutions having objects similar to the Objects, which prohibits or prohibit the distribution of its or their income and property to an extent at least as great as imposed on the Society by Clause 5 above, such institution or institutions to be determined by the members of the Society at or before the time of dissolution and, if that cannot be done, then to some charitable object.

Articles of Association

1 DEFINITIONS AND INTERPRETATION

- 1.1 In these Articles the following words and expressions shall have the following meanings:
- “the Articles” these Articles of Association of the Society;
- “clear days” in relation to a period of notice means the period excluding the day when the notice is given or deemed to be given and the day for which it is given or on which it is to take effect;
- “communication” as defined by in the Electronic Communications Act 2000 (as modified or re-enacted from time to time);
- “the Companies Act” the Companies Act 1985 including any statutory modification or re-enactment of any of its provisions for the time being in force;
- “the Council” the board of directors of the Society for the time being;
- “electronic communication” as defined in the Electronic Communications Act 2000 (as modified or re-enacted from time to time);
- “the General Secretary” the Secretary of the Society or any other person appointed to perform the duties of the secretary of the Society, including a joint, assistant or deputy secretary;
- “Member” a member of the Society for the time being whether an Ordinary Member, Honorary Member or Retired Member;
- “the Registered Office” the registered office of the Society;
- “the Regulations” the regulations of the Society made by the Council pursuant to Article 78 or any other Article;
- “the Society” the company known as “British Society for Antimicrobial Chemotherapy”;
- “the Unincorporated Society” the unincorporated association known as “British Society for Antimicrobial Chemotherapy”;
- “United Kingdom” Great Britain and Northern Ireland;
- “in writing” written, printed, lithographed, photographed or partly one and partly another, or produced by other modes of representing or reproducing words in a visible form.
- 1.2 Words importing the singular number shall include the plural number, and vice versa; words importing the masculine gender shall include the feminine gender; and words importing persons shall include corporations.
- 1.3 Unless the context otherwise requires, words or expressions contained in these Articles shall bear the same meaning as in the Companies Act or any statutory modification or re-enactment of the Companies Act in force at the date of the adoption of the Articles.

2 OBJECTS

The Society is established for the objects expressed in the Memorandum of Association of the Society.

3 THE TRUSTEES AND DIRECTORS

The members of the Council (but excluding co-optees to the Council) are charity trustees within the definition of the Charities Act 1993 (as modified or re-enacted from time to time) and also directors of the Society as the persons having the general control and management of the administration of the Society.

4 MEMBERS

The first Ordinary Members shall be the subscribers to the Memorandum of Association and those other persons who are ordinary members of the Unincorporated Society at the date of incorporation of the Society. The first Honorary Members and the first Retired Members shall be respectively those who honorary members and retired members of the Unincorporated Society at the date of incorporation of the Society.

5 There shall be the following classes of Members of the Society:

- 5.1 Ordinary Members
- 5.2 Honorary Members
- 5.3 Retired Members

- 6 A person shall not be eligible to be elected as an Ordinary Member unless he is engaged in research or education in, or development or clinical use of, antimicrobial chemotherapeutic agents.
- 7 Ordinary Members shall be elected by the Council in accordance with the Regulations and the names of Ordinary Members elected shall be disclosed at the Annual General Meeting next following their election.
- 8 Honorary Members shall be elected by Ordinary and Retired Members at an Annual General Meeting of the Society in accordance with the Regulations.
- 9 An Ordinary Member may become a Retired Member in accordance with the Regulations.
- 10 Subject to the provisions of the Articles, the Council shall by Regulations prescribe the eligibility criteria and the conditions for the acceptance for each class of Membership, the procedures for application and election to each class of Membership and the privileges of Membership.
- 11 The rights and privileges of every Member shall be personal to himself, shall not be transferable and shall cease on death.

- 12 A Register shall be kept at the Registered Office in which shall be entered the name and address of every Member.
- 13 13.1 All Ordinary Members and Honorary Members shall be entitled to attend, speak and vote at General Meetings of the Society.
- 13.2 Retired Members shall be entitled to receive notice of General Meetings and to attend and speak, but not vote, at General Meetings.

TERMINATION OF MEMBERSHIP

- 14 A Member shall cease to be a Member if:
- 14.1 by at least one month's notice in writing to the General Secretary he resigns his membership;
- 14.2 the Council or any committee of the Council, after due enquiry, resolves that the interests of the Society so require.
- 15 In the event of any Member ceasing to be a Member under Articles 14 or 17 his name shall be removed from the Register and he will not be entitled to describe himself as being a Member or to any of the privileges of a Member.

FEES AND SUBSCRIPTIONS

- 16 The fees and subscriptions for the different categories of membership shall be such sums (if any) as shall be set by the Council and shall be due on the date or dates prescribed by the Council. The Council may set different rates for different classes of Members.
- 17 A Member who is in arrears with any fee or subscription due from him and who has been notified in writing by the Council shall cease to be a Member in accordance with the Regulations and his name shall be removed from the Register of Members. The Treasurer, if authorised to do so by the Regulations, may waive or lower the sum demanded.
- 18 A Member shall remain liable to pay to the Society all fees and subscriptions due up to the date on which he ceased to be a Member.
- 19 A Member, who is in arrears with any fee or subscriptions or other sum due from him to the Society, shall not be entitled to exercise any voting rights and may have his other privileges of membership suspended in accordance with the Regulations.

REINSTATEMENT

- 20 Where any Member has ceased to be a Member for any reason, that person may only be reinstated as a Member if re-elected in accordance with Articles 7 or 8.

GENERAL MEETINGS

- 21 The Society shall hold a General Meeting in every calendar year as its Annual General Meeting in addition to any other General Meetings in the year. The Annual General Meeting shall be held on the date and at the time and place determined by the Council, and it shall be specified to be the Annual General Meeting in the notice calling it. Not more than fifteen months shall elapse between one Annual General Meeting and the next provided that so long as the Society holds its first Annual General Meeting within eighteen months of its incorporation it need not hold it in the year of its incorporation or in the following year.
- 22 All General Meetings, other than the Annual General Meeting, shall be called Extraordinary General Meetings.
- 23 23.1 The President or the Council may whenever he or it thinks fit call General Meetings and, on the requisition of not less than 5% of the Ordinary Members and Honorary Members, shall forthwith proceed to convene an Extraordinary General Meeting.
- 23.2 Any requisition shall express the object of the meeting proposed to be called and shall be left at the Registered Office.
- 23.3 Upon receipt of such requisition the General Secretary shall forthwith proceed to convene an Extraordinary General Meeting. If he does not convene one within 28 days from the date of the requisition, the requisitionists or requisitionists may themselves convene an Extraordinary General Meeting.

NOTICE OF GENERAL MEETINGS

- 24 An Annual General Meeting and an Extraordinary General meeting shall be called by at least twenty one clear days' notice. A General Meeting may, however, be called by a shorter notice if it so agreed:
- 24.1 in the case of an Annual General Meeting, by all the Members entitled to attend and vote; and
- 24.2 in the case of any other meeting by a majority in number of Members having a right to attend and vote, being a majority together holding not less than 95 percent of the total voting rights at the meeting of all the Members.
- The notice shall specify the time and place of the meeting and the general nature of the business to be transacted and, in the case of an Annual General Meeting, shall specify the meeting as such.
- The notice shall be given to all the Members, the members of Council and the auditors.
- 25 The accidental omission to give notice of a meeting to, or the non-receipt of notice of a meeting by, any person entitled to receive notice shall not invalidate the proceedings at that meeting.

PROCEEDINGS AT GENERAL MEETINGS

- 26 No business shall be transacted at any General Meeting of the Society unless a quorum of Members is present at the time when the meeting proceeds to business. Thirty persons being Ordinary Members or Honorary Members entitled to vote upon the business to be transacted and being present in person or by a proxy shall be a quorum at any General Meeting.
- 27 If such a quorum is not present within half an hour from the time appointed for the meeting, the meeting, if convened on the requisition of Members, shall be dissolved and in any other case shall stand adjourned to the same day in the next week at the same time and place or to such other day not less than seven and not more than twenty eight days after the meeting and at the time and place as the Council may determine. If at such adjourned meeting a quorum is not present within half an hour from the time appointed for holding the meeting the Members present in person or by a proxy shall form a quorum (subject to being not less than twenty persons being Ordinary Members or Honorary Members and otherwise the meeting shall be dissolved).

- 28 The President, if any, or in his absence one of the other Officers present shall preside as the chairman at Annual General Meetings and Extraordinary General Meetings, but if neither the President nor any other Officer be present within fifteen minutes after the time appointed for holding the meeting and willing to act, the members of Council present shall elect one of their number to be chairman but if there is no member of Council present and willing to act, the Ordinary Members and Honorary Members present shall elect one of their number to be chairman.
- 29 The chairman of any General Meeting may, with the consent of a meeting at which a quorum is present (and shall if so directed by the meeting), adjourn the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting other than business which might properly have been transacted at the meeting had adjournment not taken place. When a meeting is adjourned for fourteen days or more, at least seven clear days' notice shall be given specifying the time and place of the adjourned meeting and the general nature of the business to be transacted. Otherwise it shall not be necessary to give any such notice.
- 30 A resolution put to the vote of a General Meeting shall be decided on a show of hands unless before, or on the declaration of the result of, the show of hands a poll or secret ballot is duly demanded. Subject to the provisions of the Companies Act, a poll or secret ballot may be demanded:
- 30.1 by the chairman of the meeting; or
- 30.2 by at least three Members having the right to vote at the meeting; or
- 30.3 by a Member or Members representing not less than one-tenth of the total voting rights of all the Members having the right to vote at the meeting and a demand by a person as a proxy for a Member shall be the same as a demand by the Member.
- 31 Unless a poll or secret ballot is duly demanded a declaration by the chairman that a resolution has been carried or carried unanimously, or by a particular majority, or lost, or not carried by a particular majority and an entry to that effect in the minutes of the meeting shall be conclusive evidence of the fact without proof of the number or proportion of the votes recorded in favour of or against the resolution.
- 32 The demand for a poll or a secret ballot may be withdrawn before the poll or the secret ballot is taken, but only with the consent of the chairman. The withdrawal of a demand for a poll or a secret ballot shall not invalidate the result of a show of hands declared before the demand for the poll or the secret ballot was made.
- 33 A poll or secret ballot shall be taken as the chairman directs and he may appoint scrutineers (who need not be Members) and fix a time and place for declaring the result of the poll or the secret ballot. The result of the poll or secret ballot shall be deemed to be the resolution of the meeting at which the poll or secret ballot is demanded.
- 34 In the case of an equality of votes, whether on a show of hands or on a poll or a secret ballot the chairman of the General Meeting shall be entitled to a casting vote in addition to any other vote he may have.
- 35 No poll or secret ballot shall be demanded on the election of a chairman of a meeting or on a question of adjournment. A poll or secret ballot demanded on any other question shall be taken at such time and place as the chairman directs not being more than thirty days after the poll or secret ballot is demanded. The demand for a poll or secret ballot shall not prevent continuance of a meeting for the transaction of any business other than the question on which the poll or secret ballot is demanded. If a poll or secret ballot is demanded before the declaration of the result of a show of hands and the demand is duly withdrawn, the meeting shall continue as if the demand had not been made.
- 36 No notice need be given of a poll or secret ballot not taken immediately if the time and place at which it is to be taken are announced at the meeting at which it is demanded. In other cases at least seven clear days' notice shall be given specifying the time and place at which the poll or secret ballot is to be taken.
- 37 A resolution in writing signed or approved by letter, telex or facsimile transmission by or on behalf of all the Members who would have been entitled to vote upon it if it had been proposed at a General Meeting shall be as valid and effectual as if it had been passed at a General Meeting duly convened and held. Any such resolution may consist of several documents in the like form each signed by or on behalf of one or more Members.

VOTES OF MEMBERS

- 38 On a show of hands every Ordinary Member and Honorary Member present in person shall have one vote and on a poll or secret ballot every Ordinary Member and Honorary Member present in person or by proxy shall have one vote. A proxy must be an Ordinary Member or Honorary Member. No other Members shall be entitled to vote.
- 39 No objection shall be raised to the qualification of any voter except at the meeting or adjourned meeting at which the vote objected to is tendered, and every vote not disallowed at the meeting shall be valid. Any objection made in due time shall be referred to the chairman whose decision shall be final and conclusive.
- 40 The appointment of a proxy shall be in the form prescribed by the Council signed by the appointor or his duly authorised attorney.
- 41 The appointment of a proxy (and the power of attorney or other authority, if any, under which it is signed or a notarially certified copy) shall:
- 41.1 (in the case of an instrument in writing) be deposited at the Registered Office or at such other place within the United Kingdom as is specified for that purpose in the notice convening the meeting not less than forty-eight (48) hours before the time appointed for holding the meeting or adjourned meeting at which the proxy proposes to vote; or
- 41.2 in the case of an appointment contained in an electronic communication, where an address has been specified for the purpose of receiving electronic communications,
- 41.2.1 in the notice convening the meeting; or
- 41.2.2 in any instrument of proxy sent out by the Society in relation to the meeting; or
- 41.2.3 in any invitation contained in an electronic communication to appoint a proxy issued by the Society in relation to the meeting, be received at such address not less than forty-eight (48) hours before the time for holding the meeting or adjourned meeting at which the person named in the appointment proposes to vote; or

- 41.3 in the case of a poll or secret ballot be deposited or received as aforesaid not less than twenty four (24) hours before the time appointed for the taking of the poll or the secret ballot and in default of the deposit, delivery or receipt in a manner aforesaid the appointment of a proxy shall be treated as invalid.

The appointment of a proxy shall be treated as invalid twelve (12) months from its date of execution.

- 42 A vote given or poll or secret ballot demanded by a proxy shall be valid notwithstanding the previous determination of the authority of the person voting or demanding a poll or secret ballot or death of the appointor unless notice of the determination or death was received by the Society at the Registered Office or at such other place within the United Kingdom at which the instrument of proxy was duly deposited or, where the appointment of the proxy was contained in an electronic communication, at the address at which such appointment was duly received before the commencement of the meeting or adjourned meeting at which the vote is given or the poll or secret ballot demanded or (in the case of a poll or a secret ballot taken otherwise than on the same day as the meeting or adjourned meeting) the time appointed for taking the poll or the secret ballot.
- 43 In Articles 41 and 42 "address", in relation to electronic communications, includes any number or address used for the purposes of such communications.

POWERS OF THE COUNCIL

- 44 The business of the Society shall be managed by the Council who may exercise all such powers of the Society as are not required to be exercised by the Society in General Meeting. Any such requirement may be imposed either by the provisions of the statutes for the time being in force and affecting the Society or by the Articles, but no amendment to the Articles shall invalidate any prior act of the Council which would have been valid if that amendment had not been made.

COMPOSITION OF THE COUNCIL

- 45 The Council shall consist of:
- 45.1 the Officers
- 45.2 a maximum of ten Ordinary Council Members or such other maximum number (being not less than four) as may be determined by the Society in General Meeting.
- 46 The first Officers and other members of Council shall be the subscribers to the Memorandum of Association who shall hold the offices and for the terms set out in the Regulations.

ELECTION OF ORDINARY COUNCIL MEMBERS

- 47 A person will only be eligible to be elected an Ordinary Council Member if he is an Ordinary Member of the Society.
- 48 The Ordinary Council Members shall be elected by the Ordinary Members by postal ballot.
- 49 The procedure for the nomination and election of Ordinary Council Members shall be defined in the Regulations.
- 50 The results of the election of Ordinary Council Members shall be declared at the Annual General Meeting immediately following their election. The election of new Ordinary Council Members as aforesaid shall take effect as from the close of the Annual General Meeting, when the retiring Ordinary Council Members shall be deemed to retire.
- 51 An Ordinary Council Member shall hold office for a term of three years from the date of his election, at the end of which he shall retire, but shall be eligible for re-election when he has been out of office for one year. For the purposes of this Article and Articles 60, 61 and 63 a "year" shall mean the period between the end of one Annual General Meeting and the end of the next Annual General Meeting of the Society.
- 52 The Council shall have power at any time to appoint any Ordinary Member of the Society to be a member of Council, to fill a casual vacancy in the Ordinary Council Members. Any member of Council so appointed shall hold office only until the next following Annual General Meeting but he shall then be eligible for re-appointment or re-election to the Council.
- 53 The Society may by ordinary resolution, of which special notice shall have been given in accordance with Section 379 of the Companies Act, remove any member of Council before the expiration of his period of office notwithstanding anything in the Articles or in any agreement between the Society and such member of Council. The Society may by ordinary resolution appoint another person in place of a member of Council removed under this Article.

THE OFFICERS

- 54 The Officers of the Society shall be:
- 54.1 the President
- 54.2 the Vice President
- 54.3 the Treasurer
- 54.4 the General Secretary
- 54.5 the Education Secretary
- 54.6 the Grant Secretary
- 54.7 and the holder of not more than one other office(if any) as may be determined by the Council.

The Council may prescribe the duties of the Officers.

- 55 No person may at any time hold more than one of the offices.
- 56 A person will only be eligible to be elected an Officer if he is an Ordinary Member of the Society.

- 57 All Officers shall be elected by the Council by secret ballot. The procedure for the nomination and election by secret ballot of such Officers shall be as defined in the Regulations.
- 58 The results of the election shall be declared at the Annual General Meeting next following the ballot. The election of Officers as aforesaid shall take effect as from the close of the Annual General Meeting, when the retiring Officers (if any) shall be deemed to retire.
- 59 The duties of the General Secretary shall include those applicable to a secretary under the Companies Act.
- 60 All Officers (other than the Vice President and the President) shall hold office for a period of three years from their election, at the end of which they shall retire but, subject to the prior approval by the Council, be eligible for re-election for one further term of three years.
- 61 The President shall be elected one year in advance of taking up office as President and during that year shall be the Vice President of the Society. The President shall hold office for a period of three years, at the end of which he shall retire and not be eligible for re-election to that office. The immediate past-President shall hold office as Vice President of Society for two years following his retirement as President.
- 62 Upon completion of their term or terms of office, Officers shall not be eligible to stand for re-election to their previous office.
- 63 Vacancies in office shall be treated as follows:
- 63.1 In the event of the vacation of office pursuant to Article 76 or death of the President, during his third year in office, the Vice President (President-Elect) shall take up office immediately as President for the remainder of the un-expired term and shall then proceed to serve his three year term as President.
- 63.2 In the event of the vacation of office pursuant to Article 76 or death of the President during either the first and second year in office, Article 61 shall be suspended (until the election by the Council of the President under Article 63.3 and subject to the provisions of that Article) and Article 63.3 shall be enacted.
- 63.3 On the occurrence of the event in Article 63.2 the Vice-President (Past-President) shall immediately become President until such time as the next President is elected by the Council by secret ballot in accordance with the procedure for the nomination and election of Officers as defined in the Regulations and pursuant to Article 58, following which the said Vice-President (Past President) shall serve in office as Vice President (Past President) for further two years. The President so elected by the Council shall hold office for a period of three years, at the end of which he shall retire and not be eligible for re-election to that office.
- 63.4 The Council may at any time elect a person to fill a vacancy in any Office, save for the office of President the procedure for which is as defined in Articles 63.1 to 63.3, and such person must be an Ordinary Member. Any person so elected shall hold office until the next Annual General Meeting.

CO-OPTees

- 64 The Council shall have the power at any time to co-opt to the Council any person who is an Ordinary Member or Honorary Member. Any person so co-opted shall hold office until the next Annual General Meeting but may then be co-opted at any time thereafter. Any person so co-opted and the Editor in Chief shall be entitled to attend and speak at any meeting of the Council but not to vote on any question arising at a Council meeting.

PROCEEDINGS OF THE COUNCIL

- 65 Subject to the provisions of the Articles, the Council may regulate their proceedings as they think fit. The President or any three members of Council may, and on the request of the President or any three members of Council, the General Secretary shall, at any time summon a meeting of the Council by serving at least twenty eight days' notice (or such shorter notice period as may be agreed by all members of the Council) on each member of Council at his address.
- 66 Questions arising at a meeting of the Council shall be decided by a majority of votes. In the case of an equality of votes, the chairman of the meeting shall have a second or casting vote.
- 67 The quorum for the transaction of the business of the Council may be fixed by the Council and, unless fixed, shall not be less than seven members of Council, at least four of whom shall be Ordinary Council Members.
- 68 The President, or in his absence, a member of Council nominated by the President, shall chair all meetings of the Council at which he shall be present, but if at any meeting neither the President nor such nominee is willing to preside or neither is present within five minutes after the time appointed for holding the meeting, the Council present shall elect one of their number to chair the meeting.
- 69 The Council may delegate any of its powers to committees consisting of such persons as the Council may think fit. All such committees shall, in the exercise of powers so delegated, conform to any regulations imposed on them by the Council. The meetings and proceedings of all committees shall be governed by the provisions of the Articles for regulating the meetings and proceedings of the Council so far as applicable and except where these Articles or any regulations of the Council otherwise provide. All committees shall fully report their acts and proceedings to the Council as soon as is reasonably practicable.
- 70 All acts bona fide done by the Council or any of its committees, or by any person acting as a member of Council, shall, despite the later discovery that there was some defect in the appointment or continuance in office of any member of Council or of any committee or that he was disqualified, be as valid as if every such person had been duly appointed, had duly continued in office and was qualified to be a member of Council or member of the relevant committee.
- 71 The Council shall cause proper minutes to be made of the proceedings of all meetings of the Society, the Council and its committees, and all business transacted at such meetings. Any such minutes, if purporting to be signed by the chairman of the meeting or by the chairman of the next succeeding meeting, shall be sufficient evidence without any further proof of the facts stated in the minutes.
- 72 The Council may act notwithstanding any vacancy in its body, but, if and so long as its number is reduced below the number fixed by or pursuant to the Articles as the necessary quorum of members of the Council, the Council may act for the purpose of increasing the number of members of Council to that number or of summoning a General Meeting of the Society but for no other purpose.

- 73 A resolution in writing of the Council or of any of its committees signed or approved by letter, telex, facsimile transmission or cable by all the members of Council or all the members of the committee entitled to receive notice of a meeting of the Council or of its committees shall be as valid and effective as if it had been passed at a meeting of the Council or (as the case may be) its committees duly convened and held. Such a resolution may consist of several documents in the same form, each signed or approved by one or more members of Council or members of the committees of the Council, as the case may be.
- 74 All or any of the members of Council or any committee of the Council may participate in a meeting of the Council or that committee by means of a conference telephone or any communication equipment which allows all persons participating in the meeting to hear each other (subject to the Council previously approving the use of such means). A person so participating shall be deemed to be present in person at the meeting and shall be entitled to vote or be counted in a quorum accordingly. Such a meeting shall be deemed to take place where the largest of the group of those participating is assembled, or, if there is no such group where the chairman of the meeting then is.

EXPENSES

- 75 Members of the Council and of committees of the Council shall be entitled to be reimbursed proper and reasonable travelling and other out-of-pocket expenses incurred in attending meetings of the Council or of such committees or General Meetings of the Society or otherwise incurred in or about the affairs of the Society.

DISQUALIFICATION OF MEMBERS OF COUNCIL

- 76 The office of a member of Council shall be vacated if he:
- 76.1 becomes bankrupt or makes any arrangement or composition with his creditors generally; or
 - 76.2 becomes incapable by reason of mental disorder, illness or injury of managing or administering his property or affairs; or
 - 76.3 resigns his office by written notice to the General Secretary; or
 - 76.4 becomes disqualified by law from acting as the trustee of a charity or as a company director; or
 - 76.5 is removed from office by a resolution of the Society duly passed pursuant to Article 53 or Section 303 of the Companies Act; or
 - 76.6 is directly or indirectly interested in any contract or proposed contract with the Society and fails to declare the nature of his interest as required by Section 317 of the Companies Act; or
 - 76.7 is absent without the permission of the Council for three consecutive meetings of the Council and the Council resolves that his office be vacated; or
 - 76.8 ceases to be a Member.

PATRONS OF THE SOCIETY

- 77 The Council may from time to time invite persons who are eminent and distinguished to accept the office of Patron of the Society. Such persons shall enjoy such privileges as the Council may confer upon them, but shall not be entitled to vote on any motion at any of the meetings of the Council, of any committees or at any General Meeting.

REGULATIONS

- 78 The Council may from time to time make such regulations as it may think fit and add to, repeal or vary any such regulations. All regulations so made and for the time being in force shall be binding on all Members and the Council shall adopt such means as it may think fit to bring such regulations to the notice of Members. Regulations may concern the following subjects:
- 78.1 the procedure at General Meetings and meetings of the Council and its committees insofar as such procedure is not regulated by the Articles;
 - 78.2 the procedure for, and the conduct of, nominations and elections of Officers and other members of Council insofar as not regulated by the Articles;
 - 78.3 any other subjects which the Articles provide may be covered by Regulations;
 - 78.4 generally all such matters as are commonly the subject matter of company rules or bye-laws provided that no regulation shall contravene any of the provisions of the Memorandum of Association of the Society, the Articles or the Companies Act.

THE SEAL

- 79 The common seal of the Society shall only be used by the authority of a resolution of the Council or of a committee of the Council authorised for the purpose by the Council. Every document to which the common seal is affixed shall be signed by at least two persons appointed by the Council for such purpose.

ACCOUNTS

- 80 The Council shall cause proper accounting records to be kept in accordance with Section 221 of the Companies Act.
- 81 The accounting records of the Society shall be kept at the Registered Office, or subject to Section 222 of the Companies Act, at such other place or places as the Council shall think fit, and shall always be open to inspection by the members of Council.
- 82 The Council may by Regulations impose reasonable restrictions as to the time and manner at and in which the accounting records of the Company may be inspected by the Members and subject to these restrictions the accounting records shall be open to inspection by the Members during usual business hours.

AUDIT

- 83 Any appointment of Auditors required by the Companies Act and the duties of such auditors (if required) shall be regulated in accordance with Sections 236, 237, 241 and 384 of the Companies Act, the members of the Council being treated as the directors mentioned in those sections.

BANK ACCOUNT

- 84 Any bank account in which any part of the assets of the Society is deposited shall be operated by the Council and shall indicate the name of the Society. All cheques, negotiable instruments and orders for the payment of money from such account shall be signed in such manner as the Council shall from time to time determine.

INVESTMENTS

- 85 The Council shall have the power to employ as a professional investment manager for the Society any person who is entitled to carry [out an investment business under the provisions of the Financial Services Act 1986] OR [on a regulated activity under the provisions of the Financial Services and Markets Act 2000] (or any statutory modification or re-enactment thereof) and to delegate to any such manager (“the Manager”) the exercise of all or any of the power of investments on such terms and at such reasonable remuneration as the Council may see fit but always subject to the following:-
- 85.1 Delegated powers shall be exercisable only within the clear policy guidelines drawn up in advance by the Council;
 - 85.2 Every transaction carried out by the Manager under delegated powers shall be reported to the next meeting of the Council or any committee designated by the Council for such purpose;
 - 85.3 The Council shall be entitled at any time and without notice to review, revoke or alter the delegation or the terms thereof;
 - 85.4 The Council will be bound to review the arrangements for delegation at least once in every 12 months;
 - 85.5 The Manager shall keep the Council informed on a regular basis of the performance of the investment portfolio managed by the Manager.
- 86 The Council may:
- 86.1 make such arrangements as they think fit for any investments of the Society or income from those investments to be held by a corporate body which is incorporated in England or Wales (or which has established a branch or a place of business in England and Wales) as the Council's nominee; and
 - 86.2 pay reasonable and proper remuneration to any corporate body acting as the Council's nominee in pursuance of this Article.

INDEMNITY

- 87 Subject to the provisions of the Companies Act, every member of Council, or other officer or auditor of the Society, shall be indemnified out of the assets of the Society against any liability incurred by him in that capacity in defending any proceedings, whether civil or criminal, in which judgment is given in his favour or in which he is acquitted or in connection with any application in which relief is granted to him by the Court from liability for negligence, default, breach of duty or breach of trust in relation to the affairs of the Society.

DISSOLUTION

- 88 Clause 8 of the Memorandum of Association of the Society relating to the winding up and dissolution of the Society shall have effect as if its provisions were repeated in the Articles.

NOTICES

- 89 Any notice to be given to or by any person pursuant to the Articles (other than a notice calling a meeting of the Council or of any of its committees) shall be in writing or shall be given using electronic communications to an address for the time being notified for that purpose to the person giving the notice.
- 90 The Society may give any notice to a Member either personally or by sending it by post in a prepaid envelope addressed to the Member at his registered address or by leaving it at that address or by giving it using electronic communications to an address for the time being notified to the Society by the member.
- 91 Proof that an envelope containing a notice was properly addressed, prepaid and posted shall be conclusive evidence that the notice was given. Proof that a notice contained in an electronic communication was sent in accordance with guidance issued by the Institute of Chartered Secretaries and Administrators shall be conclusive evidence that the notice was given. A notice shall be deemed to be given at the expiration of 72 hours (120 hours if sent by airmail) after the envelope containing it was posted or, in the case of a notice contained in an electronic communication, at the expiration of 48 hours after the time it was sent.
- 92 In Articles 89 and 90 “address” in relation to electronic communications includes any number or address used for the purpose of such communications.

